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The effective diagnosis of infectious diseases, like tuberculosis (TB), through the 
detection of biomarkers indicative of active infection, continues to challenge the scientific 
community. Due to the consistently high burden of disease in low-income economies, there 
has been a renewed interest to transition the capabilities of the diagnostic tests from the 
research laboratory to point-of-need (PON) applications. To identify the characteristics of 
these PON tests, the World Health Organization has established the ASSURED (affordable, 
sensitive, specific, user-friendly, rapid, equipment-free, and delivered to those in need) 
guidelines. 
Using the detection of mannose-capped lipoarabinomannan (ManLAM), a TB 
biomarker, as a model system, the research presented herein focuses on approaches to meet 
the challenges faced by modern infectious disease diagnostics with an emphasis on 
transitioning state-of-the-art surface-enhanced Raman scattering (SERS) immunoassays 
toward PON applications within the framework of the ASSURED guidelines. First, we 
build on previous work investigating the underpinnings of an acid treatment method to 
improve the detection of ManLAM in the serum of infected individuals. This work 
demonstrates that while acid treatment improves the detection of ManLAM, assay 
performance is hindered because of the acid-induced degradation of ManLAM and the 





enzymatic sample treatment process, this work also shows that improved ManLAM 
recoveries lead to improved clinical accuracies.  
To increase assay performance, we developed, charactered, and validated a novel 
surface-enhanced resonance Raman scattering (SERRS) immunoassay. This improves the 
limit of detection (~10x) and analytical sensitivity (~39x) for ManLAM measurements 
compared to an analogous SERS immunoassay. The remainder of the work validates the 
use of a handheld Raman spectrometer for the detection of phospho-myo-inositol-capped 
LAM (PILAM), a ManLAM simulant. This work demonstrates the ability to achieve low 
limits of detection (~0.2 ng/mL) for PILAM in human serum and document the impact of 
excitation wavelength and the plasmonic coupling between the labels and planar gold 
substrates as a basis for further improvements in SERS immunoassays. Taken together, 
this work begins to establish approaches for improved methodologies to combat the burden 
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 The early and effective diagnosis of infectious diseases through the detection of 
biomarkers indicative of pathogenic agents continues to challenge the scientific and 
medical community. Efforts to improve existing diagnostic methods as well as to develop 
novel detection strategies for disease biomarkers have seen renewed interest in recent years 
due to the emergence of new disease strains and the consistently high burden of disease. 
As an example, The World Health Organization (WHO) reports that tuberculosis (TB) has 
surpassed human immunodeficiency virus infection and acquired immune deficiency 
syndrome (HIV/AIDS) as the world’s deadliest infectious disease, with an estimated 1.37 
million deaths worldwide in 2015.1-2 This report also indicates that the greatest impact of 
infectious diseases is experienced by low-income economies, where infectious diseases 
accounted for 5 of the top 10 leading causes of death in 2015 (table 1.1).1-2 The work in 
this Dissertation focuses on improving existing infectious disease diagnostic modalities 
and on developing novel detection strategies designed to transition today’s laboratory 
bound tests to a point-of-need (PON) platform. TB will be used as a proving ground for all 
of this work. 
2 
 
Table 1.1. Leading causes of death in low-income economies worldwide in 2015.2 
Rank Description 
Estimated number of deaths 
per 100,000 population 
1 Lower respiratory infections 84.9 
2 Diarrheal disease 57.2 
3 Stroke 49.6 
4 Ischemic heart disease 48.6 
5 HIV/AIDS 47.7 
6 Tuberculosis 34.5 
7 Malaria 34.4 
8 Preterm birth complications 32.1 
9 Birth asphyxia and birth trauma 30.5 
10 Road injuries 28.5 




The sensitive detection of disease-related biomolecules can have a strong positive 
impact on patient outcomes by enabling diagnosis and subsequent treatment earlier in the 
disease’s progression.3-4 Additionally, these approaches may have merit in use as part of 
disease surveillance systems, limiting the spread of infectious diseases and reducing the 
disease burden.5 However, the effectiveness of a diagnostic test depends on a number of 
factors such as sensitivity, cost, analysis time, and reliability. Other issues include the 
accessibility to a patient population, availability of local infrastructure and technical 
expertise, and societal attitudes towards health care.1, 5-6  
 Building on previous work in our laboratory on the development of a novel 
immunoassay for TB diagnostics, this Dissertation is focused on further improvements in 
the platform. This Dissertation is organized into five chapters. The first chapter, the 
Introduction, provides context for this work by describing the ideal characteristics of a 
diagnostic test and the important techniques used throughout. The second chapter 
investigates the underpinnings of sample treatment as a means to liberate a marker 
indicative of TB infection from a human serum matrix and how sample treatment markedly 
improves clinical accuracy. The third chapter describes the development of a novel sensing 
strategy that is based on surface-enhanced resonance Raman scattering (SERRS) and 
reports on a measurement of its performance with respect to TB biomarker detection. The 
fourth chapter investigates the utility of a handheld Raman spectrometer for TB marker 
measurements with emphasis on the challenges associated with transitioning a new 
measurement technology from the laboratory benchtop to the field. The fifth and final 




1.2 Infectious Disease Diagnostics (Tuberculosis as a Model System) 
A brief definition for a diagnostic test in the medical field is one that detects the 
presence of disease. For applications in infectious disease diagnostics, most tests are 
designed to detect a biomolecule specific to a given pathogen or the pathogen itself. These 
tests can be qualitative or quantitative, their primary function being to provide health care 
providers the necessary information to make an informed decision on diagnosis and 
treatment. The effectiveness of a diagnostic test is framed by its clinical accuracy.7-10 
Clinical accuracy is comprised of two components: (1) clinical sensitivity, which is the 
ability of the test to correctly identify an infected patient as a true positive (TP) relative to 
missing infected patients, as false negatives (FN); and (2) clinical specificity, which is the 
ability of the test to correctly identify noninfected patients as a true negative (TN), relative 
to misdiagnosing noninfected patients as false positives (FP). Clinical sensitivity and 
clinical specificity, expressed as percent, are summarized in equations 1.1 and 1.2, 
respectively.8  
 
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝑆𝑆𝑆𝑆𝐶𝐶𝑆𝑆𝐶𝐶𝑆𝑆𝐶𝐶𝑆𝑆𝐶𝐶𝑆𝑆𝑆𝑆 =  𝑇𝑇𝑇𝑇




𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝑆𝑆𝑆𝑆𝑆𝑆𝐶𝐶𝐶𝐶𝑆𝑆𝐶𝐶𝐶𝐶𝐶𝐶𝑆𝑆𝑆𝑆 =  𝑇𝑇𝐹𝐹
𝑇𝑇𝐹𝐹 + 𝐹𝐹𝑇𝑇  ×  100         (1.2) 
 While an effective diagnostic test must be clinically accurate, the real-world 
effectiveness of a test is strongly dependent on a large number of extrinsic factors. These 
include a balance between clinical accuracy and the cost per test, turnaround time, technical 
complexity, and accessibility.5, 11-15 Patients in high-income economies often have less to 
fear from these extrinsic factors as there are typically testing redundancies in place to 
ensure rapid and accurate diagnosis.16 In fact, infectious diseases like TB are not found 
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among the leading causes of death in upper-middle and upper-income economies.2 
However, the effect on lower-middle and lower-income economies can be devastating.1-2 
Often, low-income and resource-limited areas where many infectious diseases like TB are 
endemic, such as equatorial Africa and Asia, have compounding factors that further hinder 
the effectiveness of a given diagnostic method.1-2, 5, 17 
 In many resource-limited economies, the effectiveness of a diagnostic test can also 
be affected by the lack of adequate medical facilities and skilled personnel, and poor 
infrastructure in terms of electrical power and clean water.5 The consistently high economic 
and societal burden caused by infectious diseases has fueled research efforts aimed 
specifically at effective PON testing methods to circumvent these challenges.5 As 
guidance, the WHO has set forth the ASSURED (affordable, sensitive, specific, user-
friendly, rapid, equipment-free, and delivered to those in need) criteria to describe the 
characteristics of an ideal PON test.17-18 It is important to note that recent iterations have 
amended the equipment requirement to include inexpensive and robust portable 
equipment.5, 19 The development of an effective PON test for TB begins to address the 
elements of the ASSURED criteria, and research aimed at overcoming challenges in 
meeting these criteria serves as the underlying context for this Dissertation.  
 TB is caused by a bacterial infection of Mycobacterium tuberculosis, (Mtb). In 
addition, while treatment options (i.e., antibiotics) are available, effective diagnostic 
methods suitable for PON applications are lacking.1, 5, 15 The gold standard for TB testing 
rests on a well-established bacterial culture method.1, 20 Because Mtb is a slow growing 
bacterium, this test can take several weeks and requires sophisticated medical facilities and 
highly trained personnel.1, 20-22 Serological tests for TB are available, but the poor 
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diagnostic performance of these tests caused the WHO to call for a ban of such tests in 
resource-limited regions.23-24 This leaves clinical suspicion and a relatively quick sputum 
smear microscopy (SSM) test as the most common approaches for TB diagnosis in PON 
settings.25 However, both SSM and bacterial culture are only reliable at advanced stages of 
infection, limiting the potential benefits of early detection.25 Furthermore, SSM and 
bacterial culture are ineffective for diagnosing extrapulmonary TB, which accounts for 
~10% of infections worldwide.1 As a consequence of the testing limitations, it is estimated 
that 1 in 3 infected individuals go undiagnosed/unreported.1 Previous work in our 
laboratory focused on the development of a simple immunoassay-based test for a TB 
biomarker, specifically lipoarabinomannan (LAM), figure 1.1, as a means to address many 
of the challenges faced with diagnosing TB.26-27  
Using TB as a proving ground, this Dissertation builds on this past work in an effort 
to fill in the void left by today’s diagnostic tools. It is important to note there are two forms 
of LAM used throughout this work: (1) phospho-myo-inositol-capped LAM (PILAM), 
which is derived from Mycobacterium smegmatis (Msm) and serves as a nonpathogenic 
simulant suitable for TB diagnostic assay development, and (2) mannose-capped LAM 
(ManLAM), which is indicative of pathogenic Mtb.28-35 Both are carbohydrate molecules 
found in the bacterial cell wall and have similar molecular weights, 17.3±5.0 kDa.28-30, 36-
39 While the exact degree of branching and extent of capping agents may vary somewhat, 









Figure 1.1. Representative structure of lipoarabinomannan (LAM): (1) 
phosphatidylinositol mannoside (PIM2) anchor, (2) mannan core, (3) arabinan side 
chains, and (4) capping motifs. The branching, capping motifs, and overall molecular 
weight vary somewhat across different mycobacteria. Both phospho-myo-inositol-
capped LAM (PILAM) from nonpathogenic M. smegmatis and mannose-capped 
(ManLAM) from M. tuberculosis are used throughout this work.40 
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1.3 Immunoassays as Diagnostic Tools 
 Immunoassays as a modern diagnostic tool can be traced to work by Landsteiner et 
al. on the detection of haptens in 1945.41 An immunoassay relies on antibodies as molecular 
recognition elements to improve the sensitivity and selectivity of a diagnostic platform.42 
Continued research in this area led to the development of a solid-phase immunoassay (SPI), 
which had improved sensitivity relative to the typical radioimmunoassays available at the 
time; and, due to its ease of use, the basic format is still in use today.43 Figure 1.2 
summarizes the principal components of a typical SPI, including (1) the solid support, 
which is modified with an antibody to selectively capture the target analyte, and (2) a 
labeling method using a tracer antibody, which selectively labels the captured analyte. Due 
to the heterogeneous nature of SPIs, excess solution and interfering molecules can be easily 
rinsed away before the labeling step, leading to a significant improvement compared to the 
previously used cleanup methods (e.g., ion exchange, electrophoresis, gel filtration, and 
precipitation techniques).43 SPIs are incredibly flexible platforms and are compatible with 
a wide range of detection strategies based on spectroscopic techniques (e.g., absorption, 
fluorescence, and chemiluminescence), electrochemical techniques, and scintillation 
counting, depending on the chemical label affixed to the tracer antibodies.44-48 To further 
expand the utility of SPIs, recent work has focused on the development of nanoparticle-
based detection strategies, including quantum dots and noble metal nanoparticles for 
spectroscopic detection, and magnetic nanoparticles for detection by giant 
magnetoresistance.49-59 A more detailed overview of enzyme-linked immunosorbent assays 
(ELISAs) and immunoassays based on surface-enhanced Raman scattering (SERS) 






Figure 1.2. Example formats for solid-phase immunoassays with emphasis on the labels 
used in enzyme-linked immunosorbent assays (ELISA) and surface-enhanced Raman 
scattering (SERS) immunoassays for the detection of tuberculosis biomarkers. The two 
assays are operationally similar, but the SERS immunoassay used a gold nanoparticle 
based label, which is designed to intrinsically amplify the response with respect to 
antigen capture as opposed to the enzymatic amplification of ELISA. Figure 1.3 
overviews the format for ELISA. 
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is presented in the following section. 
 
1.4 The Enzyme-linked Immunosorbent Assay (ELISA) and Surface- 
enhanced Raman Scattering (SERS) Immunoassay 
 ELISA emerged in the early 1970s and, as described by Van Weemen et al., uses 
an enzyme as the basis for a detection strategy.60 These assays rely on the extrinsic signal 
amplification from an enzyme-tagged antibody binding to a captured antigen on the 
surface, caused by the high turnover rate of the enzyme for its substrate that produces a 
highly colored or fluorescent product; this type of assay has been extensively reviewed 
elsewhere.44, 61-63 Much of the work described in Chapter 2 utilizes a tracer antibody that 
we functionalize with horseradish peroxidase that, during the color development step, 
facilitates the oxidation of 3,3',5,5'-tetramethylbenzidine to 3,3',5,5'-tetramethylbenzidine 
diimine, which absorbs strongly at 450 nm, for spectroscopic detection (figure 1.3).64 
Despite widespread use, ELISAs have some key limitations, particularly when attempting 
to transition a detection strategy from the highly controlled environment of the research 
laboratory to a PON setting. Changes in the reaction environment of the enzyme (e.g., 
temperature, pH, and ionic strength) can change the enzymatic activity altering the 
performance of the assay.62, 65 Enzymatic activity can also be degraded by denaturation due 
to the conjugation chemistries used to link the enzyme to the tracer antibody.66 Finally, 
while ELISAs are extensible (i.e., they have been employed to detect different analytes by 
changing the capture and tracer antibodies), their application for multiplexed detection (i.e., 
the detection of multiple analytes simultaneously) is limited by the overlap of the large 







Figure 1.3. Depiction of the oxidation of colorless 3,3',5,5'-tetramethylbenzidine to the 
highly colored 3,3',5,5'-tetramethylbenzidine diimine. 
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 To overcome the limitations of ELISA and many other detection strategies, our 
laboratory was among the first to develop a SERS immunoassay for disease marker 
detection.55-56 Unlike ELISA, the SERS immunoassay for the detection of TB biomarkers, 
PILAM and ManLAM, uses the intrinsic signal enhancement arising from functionalized 
gold nanoparticles, or extrinsic Raman labels (ERLs), that plasmonically couple with the 
underlying gold support (figure 1.4), for highly sensitive detection.26-27, 69 While some 
aspects of the enhancement mechanism are still under investigation, it is now widely 
accepted that the signal enhancement of the traditionally weak Raman phenomena derives 
primarily from an electromagnetic enhancement mechanism.70-74 The electromagnetic 
enhancement derives from the amplification of an electric field by localized surface 
plasmon resonance.55-56, 70-79 When using a smooth gold substrate to support the capture 
antibody, the plasmonic interactions between the gold nanoparticle and gold substrate 
further amplify the response.55-56, 70-79 Enhancement factors of 105-106 are typical, but can 
be up to 1014 in a few isolated instances.72, 74, 80-82 The theory and mechanism of the SERS 
enhancement mechanism have been refined since the discovery of SERS in the early 70s.71-
72, 80 Research has also investigated the impact of size, shape, and composition of the 
nanoparticle, and the influence of the dielectric properties of the surrounding medium.73, 
76, 83-88 
SERS immunoassays have several advantages compared to ELISAs. The 
electromagnetic enhancement mechanism results in a signal intensity comparable to or 
greater than those from fluorescence-based detection.59, 89-90 Raman bands are ~40x 
narrower than typical fluorescence or absorption bands, reducing the potential spectral 






Figure 1.4. Depiction of the surface-enhanced Raman scattering immunoassay readout 
and the Raman spectra of the Raman reporter molecule, 5,5‘-dithiobis (succinimidyl-2-
nitrobenzoate) (DSNB), on the nanoparticle surface. The height of the symmetric nitro 
stretch, νs(NO2), of DSNB at 1336 cm-1 is used to indirectly quantify the labeled antigen 
on the surface after its capture by immobilized surface antibodies and subsequently 
labelling with the nanoparticle-based label. 
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immunoassays.72, 91-92 Because the plasmonics of the system is tunable, background 
fluorescence is reduced by the use of longer wavelength excitation sources, such as HeNe 
lasers at 633 nm.93 Alternatively, as discussed in Chapter 3, exploiting the intrinsic 
electronic transitions of a RRM can be used to further improve the detection strength in 
SERRS-based immunoassays. In addition, SERS detection is attractive as a method to 
facilitate PON applications, because it is less affected by environmental factors, such as 
pH, ionic strength, and natural quenchers like oxygen.93 Given these advantages, Chapter 
4 explores the transition of SERS towards a PON platform using inexpensive and reliable 
handheld spectrometers.94-96 Chapter 5 included a summary of the conclusions from this 
work as well as briefly discusses the future direction of these projects. 
 
1.5 Surface-enhanced Resonance Raman Scattering (SERRS) 
 SERRS is a special case of SERS in which the excitation wavelength induces an 
electronic transition in the Raman reporter molecule.97-100 This can result in an increase in 
signal by as much as a 106.79 In the late 1990s, Nie et al. reported single molecule detection 
for a fluorescent dye on colloidal silver aggregates.98 They found that while the majority 
of the signal enhancement derives from the SERS mechanism, the electronic excitation of 
the dye molecule with the 514 nm source also contributed to the overall signal 
enhancement.98 Since then, SERRS has been used to study conformational changes in 
proteins, for multiplexed measurements of DNA oligonucleotides, intracellular imaging 
and detection, and the detection of waterborne pathogens.101-104 Despite the sensitive 
detection achievable with SERRS measurements, it has seen relatively few applications 
compared to SERS, in part due to the difficulty in maintaining stable colloidal labels once 
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they have been modified with a resonance-enhancing dye.79 While there are reports of 
researchers attempting to circumvent this issue by functionalizing a planar substrate with 
the RRM to allow for subsequent detection by SERRS, this area of study is somewhat 
limited with respect to the detection of disease biomarkers for infectious disease 
diagnostics.79, 103, 105-106 Chapter 3 describes the development and application of a novel 
chemically modified SERRS immunoassay for the detection of ManLAM from whole 
serum.  
 
1.6 Sample Preparation in Diagnostics 
 “Matrix effects” is a term broadly applied in diagnostics, and is ascribed to the 
deleterious effects that ancillary components in a sample matrix can have on analyte 
detection.107 Matrix effects can limit assay sensitivity and reproducibility, and as such, the 
reduction or management of matrix effects can be a critical component in the development 
of an analytical measurement.107-108 Much of the work described herein revolves around 
the detection of PILAM and ManLAM in human serum, the part of blood remaining after 
separation from whole cells and clotting factors.109 Human serum is a complex biological 
sample matrix containing proteins, polysaccharides, fatty acids, electrolytes, and numerous 
other small molecules that may interfere with analyte detection. 107, 110-111 The Human 
Metabolome Database, a multiagency initiative, currently contains 74,461 unique 
metabolomic entries, and it is linked to several other databases that add to this number.112-
114 Because of the complexity of human serum and the negative effects endogenous serum 
components can have on analyte detection in immunoassays, a large number of methods 
have been developed to limit matrix effects.62, 107-108 
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 As found in our laboratory, and well documented in the literature, matrix effects 
often manifest in two ways when developing immunoassay methodologies for use in 
human serum.26-27, 107-108, 115 First, surface passivation, in which specific or secondary 
interactions occur between the antibody-modified capture surface and serum proteins, can 
block the surface from binding a target analyte.47, 62, 108 Second, the formation of protein-
analyte complexes can inhibit the capture or labeling of the analyte.62, 108 Formation of 
complexes is a known issue in TB diagnostics. It has been shown that TB markers like 
ManLAM shed from Mtb during the course of infection can form complexes with proteins 
in human serum.26-27, 31, 116-127  
Methods to disrupt protein complexes vary from single-step treatments that require 
no further processing to multistep separations that remove the treatment agent and 
renormalize the sample matrix before performing an assay. As an example of a single-step 
treatment method, diluting the serum sample with a suitable buffer matrix is often effective 
at limiting matrix effects, by simply decreasing the concentration of the offending species 
until its effect is lowered to an acceptable level.107, 128 However, when attempting to detect 
an analyte like ManLAM at extremely low concentrations, this method dilutes the analyte, 
adding to the detection challenge. More complex multistep procedures have been 
developed to more selectively denature proteins. Multistep methods can include the use of 
organic solvents, salts, detergents, heat, and acids. 92, 113-117 These methods denature 
proteins by affecting the electrostatic and hydrophobic interactions within the protein, 
ultimately leading to noncovalent aggregation.108, 129-133 Finally, a popular treatment 
method employed in DNA tests and proteomics uses serine proteases like trypsin and 
proteinase K (PK) to denature serum proteins.134-136 For example, PK is a broad spectrum 
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protease and, given the proper conditions, can effectively reduce proteins to small 
fragments that can be removed during a subsequent heating step. PK is often used to isolate 
DNA segments from serum samples for polymerase chain reaction analysis.135, 137  
One of the treatment procedures used in this Dissertation builds on our previous 
work that describes the initial development and application of a perchloric acid (PCA) 
treatment method to facilitate the low level detection of PILAM and ManLAM from human 
serum.26-27 This approach is overviewed in figure 1.5. The PCA treatment method seems 
ideal, at first glance, as it is rapid, inexpensive, and easy to use. The change in pH 
protonates the carboxylate groups of proteins which, when combined with the ability of the 
acid to hydrolyze proteins, drives the noncovalent aggregation of these serum proteins.133, 
138-146 As described in some of the original work using trifluoracetic acid for protein 
removal, the effect of acid treatment is dependent on protein size. 139, 144, 146 Larger proteins 
precipitate from solution more readily than smaller proteins, meaning the method can be 
tailored to target specific size ranges of proteins by varying the amount of acid added.139, 
144, 146 However, treatment methods that denature proteins can change subsequent activity, 
indicating the proteins may have been permanently degraded in the process.144, 147 As such, 
a major focus of this Dissertation details an investigation into the challenges associated 
with use of a PCA treatment method to improve the detection of ManLAM in human serum 
and enhance clinical accuracy of our diagnostic platform. 
 
1.7 Dissertation Overview 
 The majority of the work in this Dissertation builds on the above subject areas with 






Figure 1.5. Step-by-step depiction of the perchloric acid-based sample treatment method 
used to improve the detectability of PILAM spiked in serum samples. The majority of 
the protein is removed due to the noncovalent aggregation induced with the addition of 
acid (Step 1). This is followed by a separation and transfer step to separate the PILAM-
containing supernatant from the denatured protein (Steps 2-3). Finally, the solution is 




Moreover, the platform described herein is extensible to addressing challenges faced by 
many new and existing disease diagnostic tests. Chapter 2 describes the investigation of 
methodologies to recover ManLAM from human serum, while maintaining its 
detectability. This chapter concludes with a study detailing how the recovery of ManLAM 
affects the clinical accuracy of an ELISA test designed for TB diagnostics when assaying 
patient samples. Chapter 3 describes a novel chemical-based, resonance-enhancing 
substrate for SERRS detection that has the potential to improve assay sensitivity while also 
beginning to circumvent the requirement for sophisticated research-grade instrumentation. 
Chapter 4 builds on the theme of transitioning sophisticated laboratory-based diagnostics 
towards a PON platform through the validation of a handheld Raman spectrometer and its 
applicability in detecting and quantifying PILAM from a complex sample matrix. Finally, 
Chapter 5 includes a summation of the work described herein, as well as a brief discussion 
regarding future directions of this work and its context in the realm of infectious disease 
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INVESTIGATING METHODS TO IMPROVE THE DETECTION OF MANNOSE-
CAPPED LIPOARABINOMANNAN FOR TUBERCULOSIS DIAGNOSTICS 
 
2.1 Introduction 
A recent report by the World Health Organization (WHO) estimates there were 1.37 
million deaths associated with tuberculosis (TB) infections in 2015.1 While timely 
treatment often results in positive patient outcomes (83% success rate for nondrug-resistant 
TB)1, the early and accurate diagnosis of TB remains a significant technical barrier to 
reducing mortality. The impact of TB is especially burdensome in low- to middle-income 
countries (LMICs), where limited access to healthcare, economic barriers, and social 
stigma results in 1 in every 3 infected individuals remaining undiagnosed or unreported.1-
4 This unfortunate set of circumstances places the development of a rapid, accurate, and 
low-cost TB test as a vital step in ultimately reducing the consequences associated with TB 
infection.5-6 This Chapter investigates the impact of sample treatment on an antigenic 
marker for the clinical diagnosis of TB patient samples, as a potential means to reduce the 
burden of disease associated with TB. 
The most common point-of-need (PON) diagnostic test for TB screening used in 
LMICs today is sputum smear microscopy (SSM), a reflection of its relatively rapid turn-
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around time, low cost, and ease of use.7 This methodology, however, requires an advanced 
stage of infection in order to be effective, which severely limits its utility for early stage 
diagnosis.7 The gold standard for TB diagnosis is bacterial culture of sputum samples.1, 8 
While having a high clinical accuracy, this method has a turnaround time of a few weeks, 
requires a sophisticated laboratory infrastructure for effective implementation, and cannot 
diagnose extrapulmonary TB, which accounts for ~10% of all TB cases.9-11 New nucleic 
acid amplification tests (NAATs) also have a high level of diagnostic accuracy and have 
shown promise in detecting patients with extrapulmonary TB, but their high cost and 
limited ease of use continue to hinder their widespread usage in PON applications.12-15  
In light of these challenges, a number of recent studies have focused on the 
development of tests for the direct detection of primary antigenic markers of 
Mycobacterium tuberculosis (Mtb), the causative agent of TB, in serum, urine, and other 
body fluids.16-18 One marker in particular, mannose-capped lipoarabinomannan 
(ManLAM), has been the subject of several investigations regarding its utility as a clinical 
marker for TB infection.19-26 ManLAM is a highly branched lipoglycan (17.3±5.0 kDa) 
that makes up roughly 40% of the mycobacterium cell wall. 27-31 While the exact structure 
(e.g., degree of branching and extent of capping motifs) can vary somewhat, a 
representative structure of ManLAM is shown in scheme 2.1.27-29, 32 The potential value of 
ManLAM as a marker arises from the fact that it is unique to mycobacteria and it is a major 
virulence factor in the infectious pathology of Mtb.33-34 Moreover, ManLAM is readily 
shed from Mtb into the circulatory system, meaning the presence and quantity of ManLAM 
is strongly linked to active TB infection.20, 30, 35-36  





Scheme 2.1. Representative structure of lipoarabinomannan (LAM): (1) 
phosphatidylinositol mannoside (PIM2) anchor, (2) mannan core, (3) arabinan side 
chains, and (4) capping motifs. The branching, capping motifs, and overall molecular 
weight vary somewhat across different mycobacteria. Mannose-capped LAM 
(ManLAM) is from M. tuberculosis and is used in this work. The red arrows indicate the 
5-α-arabinofuranosyl and 2-α-arabinofuranosyl components, the groups most 





clinical specificities (i.e., the reliability of a test to correctly identify a healthy patient as 
healthy), but widely varied clinical sensitivities (i.e., the reliability of a test to correctly 
identify a sick patient as sick).37-38 As we recently demonstrated, one important contributor 
to the poor clinical sensitivity of these measurements is the complexation of ManLAM 
with endogenous proteins and other constituents in serum, which hinders detection (capture 
and/or labeling) in a sandwich immunoassay.20, 39-42 
Along these lines, we reported that the treatment of phospho-myo-inositol-capped 
lipoarabinomannan LAM (PILAM) that had been spiked into human serum with a 
perchloric acid (PCA) treatment process significantly improved the detection of PILAM in 
a sandwich immunoassay.43 PILAM is a cell wall analog to ManLAM, but originates from 
M. smegmatis, which is frequently used as a nonpathogenic model organism for Mtb.44-45 
Our work demonstrated that denaturing the proteins in PILAM-spiked serum samples 
through acidification with PCA improves detection limits for this simulant by ~1500x.43 
We subsequently found that treatment of serum spiked with ManLAM and then processed 
with PCA enabled the detection of ManLAM at levels ~250x lower than that for the same 
samples in the absence of PCA treatment.46 We also showed that when applying PCA 
treatment to a pilot set of TB patient specimens [24 TB-positive specimens (culture-
confirmed), and 10 healthy controls], ManLAM was measurable in 21 of the 24 TB-
positive specimens, but was not detectable in any of the healthy controls.46 While 
recognizing that this study used a very small specimen set, these results provided important 
evidence for the potential utility of ManLAM as a TB marker and demonstrated the need 
for the further development of a sample treatment method to disrupt complexation and 
further enhance the detection of ManLAM in human serum. 
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This Chapter reports on ongoing efforts to delineate the impact of PCA treatment 
on the detection of ManLAM in serum using an enzyme-linked immunosorbent assay 
(ELISA)47-50 (scheme 2.2). The goal of this work is to gain further insights into the possible 
pathways by which sample treatment improves ManLAM detection. The initial results 
from this effort indicate that while PCA treatment improved ManLAM detection, the 
amount of ManLAM actually measured was ~75% lower than spike in levels. We therefore 
hypothesized that there were three possible origins for this low recovery: (1) passivation 
of the capture surface by materials in the pretreated serum; (2) degradation of ManLAM 
due to its susceptibility to acid hydrolysis as investigated through filtration of degraded and 
intact ManLAM; 26-28, 51 and (3) the inability of PCA acidification to fully release ManLAM 
from complexation. The impact of each of these processes are investigated herein. The 
final aspect of this work explores the impact of ManLAM recovery from patient samples 




 Dulbecco’s PBS buffer packs (10 mM PBS and 150 mM NaCl), StartingBlock 
(SB), 3,3ʹ,5,5ʹ-tetramethylbenzidine (TMB), and proteinase K (PK, 28.9 kDa) were 
purchased from Thermo Scientific. All buffers were prepared with 18.2 MΩ H2O, purified 
by a Barnstead ultrapure water system. Dithiothreitol [(DTT) ≥ 99%] was purchased from 
Acros Organics and fresh 250 mM solutions were prepared in PBS buffer immediately 
before each experiment. Chloroform, Tween 20 (T20), 70% PCA, and potassium carbonate 





Scheme 2.2. Depiction of the enzyme-linked immunosorbent assay format including: (1) 
the antibody functionalized solid support; (2) the exposure to antigen-containing 





acetic anhydride, 3-OMe glucose, bovine serum albumin (BSA), and concentrated sulfuric 
acid were obtained from Sigma Aldrich. Sulfuric acid (2N) was prepared by dilution with 
purified water. High affinity polystyrene 96-well microplates (Costar 3590) were 
purchased from Corning International. Pooled AB human male serum, hereafter referred 
to simply as human serum, was acquired from Innovative Diagnostics Inc. Streptavidin-
modified horseradish peroxidase (HRP) and microplate sealers were obtained from R&D 
Systems.  
A VF-5ms (5% phenyl methylpolysiloxane) chromatography column was obtained 
from Agilent. 13C5-D-arabinose was purchased from Cambridge Isotope Laboratories. A 
polyclonal rabbit antibody for Mtb (PABL), which served as the capture antibody, was 
acquired and used as received from Virostat (Cat. No. 4601). The ELISA tracer antibody, 
a monoclonal antibody (A194-01) for Mtb, was provided by Dr. Abraham Pinter at Rutgers 
University. ManLAM was isolated and purified by Dr. Delphi Chatterjee’s laboratory at 
Colorado State University.29, 52 Sulfo-NHS Biotin and Zeba Spin desalting columns, 0.5 
mL sample volume with a molecular weight cut off (MWCO) filter of 7 kDa, were obtained 
from Thermo Scientific. Additional Amicon 3 kDa MWCO filters were acquired from 
EMD Millipore. A biotin quantification kit was purchased from Pierce Biotechnology and 
used following the package insert. TB-suspect patient samples were supplied by the 
Foundation for Innovative and New Diagnostics (FIND). 
 
2.2.2 Enzyme-linked Immunosorbent Assay (ELISA) 
 ELISA experiments were performed using high affinity 96-well microplates. To 
prepare a functionalized capture surface, PABL was diluted to 10 µg/mL in PBS, and 100 
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µL of the diluted solution was added to each well. The plates were sealed and incubated at 
2-8° C for ~16 h to coat the wells with physisorbed antibody. The plate was then placed in 
a VorTemp™ incubator and rocker platform at a temperature of 30 °C and rotated at 250 
RPM for 30 min. The capture antibody solution was removed by aspiration and the 
microwells rinsed. The aspiration and rinse steps were performed between each of the 
following assay steps (i.e., blocking, antigen incubation, labeling, and HRP incubation) 
using a BioTek MultiFlo™ FX automated plate washer. Each rinse cycle was repeated 
three times using 300 µL of PBS with 0.05% Tween 20 (PBST) (v/v) at a flow rate of 422 
µL/s (~1.49 m/s). Next, 200 µL of SB was added to each well and incubated for 1 h in the 
VorTemp™ incubator and rocker platform (30 °C and 250 RPM) in order to passivate 
uncoated portions of the polystyrene surface. All subsequent steps (i.e., antigen incubation, 
labeling, and HRP incubation) used the same conditions. ManLAM solutions for these 
experiments were prepared in PBS, PBS containing 1% BSA, and human serum with and 
without PCA treatment. After preparation, 100 µL of the ManLAM-containing samples 
were added to the plate and incubated for 2 h.  
Biotinylation of the A194-01 monoclonal antibodies followed the EZ-Link Sulfo-
NHS-Biotin standard protocol provided by Thermo Scientific.53 In brief, a 10 mM sulfo-
NHS biotin solution was added at 50 times molar excess to a 1 mg/mL (6.7x10-6 M) 
solution of antibody and kept on ice for 3 h. Excess biotin was removed using a Zeba Spin 
desalting column by centrifuging at 1358 g for 1 min. The concentration of antibody and 
extent of biotinylation was determined to be 1.01±0.01 mg/mL with a biotin-to-antibody 
ratio of 3.65:1, as measured using the Pierce biotin quantification kit. The modified 
A194-01 antibody was diluted to 200 ng/mL in PBS for the labeling step of the assay. 
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Captured ManLAM was labeled by adding 100 µL of the diluted tracer antibody to 
each well for 2 h. After the stock Streptavidin-HRP solution was diluted 1:200 in PBS, 100 
µL of the solution was added to each well and incubated for 25 min. Color development 
was performed by adding 100 µL of TMB per well and incubating for an additional 25 min 
before the addition of 50 µL of a 2 N H2SO4 stop solution. The absorbance of the solution 
in the wells was immediately measured at 450 and 570 nm using a BioTek ELx800™ plate 
reader. The reported absorbances equal the absorbance at 450 nm minus that at 570 nm.  
 
2.2.3 Acid Treatment Procedure 
 The PCA treatment of ManLAM-spiked serum samples has been described in our 
previous work.43, 46 In brief, the samples are acidified to pH ~1 in order to denature serum 
proteins through the addition of 4 µL of PCA per 100 µL of sample. The samples are then 
vortexed for 10 s and immediately centrifuged at ~12,000 g for 5 min to pellet denatured 
proteins and other aggregated materials. A portion of the resulting clear supernatant 
containing the ManLAM is transferred to a new microcentrifuge tube that contains 9 µL of 
2.0 M K2CO3 per 100 µL of starting sample volume to neutralize the samples to pH ~7.5. 
These samples are then stored at 2-8 ºC for 60 min to accelerate precipitation of KClO4, 
after which the samples are centrifuged for 5 min at 270 g to ensure the precipitate has 
settled. The ManLAM-containing supernatant is transferred to a new microcentrifuge tube 






2.2.4 Proteinase K (PK) Treatment Method  
 In brief, stock solutions of 250 mM DTT and 20 mg/mL PK were prepared in PBS 
~30 min before use. PK and DTT were added to the samples to final concentrations of 200 
µg/mL and 5.0 mM, respectively. The overall change in sample volume was ~1%. The 
samples were incubated for 60 min using the VorTemp™ at 50° C and 250 RPM. PK was 
then inactivated by heating the solution to 95-100° C for 10 min, which also promotes the 
noncovalent aggregation of denatured serum proteins.54-56 Finally, the samples were 
centrifuged at 12,000 g for 10 min, after which the clear, ManLAM-containing supernatant 
was transferred to a new microcentrifuge tube. The solution was equilibrated to ambient 
laboratory conditions before running the assay for ManLAM. 
 
2.2.5 Carbohydrate Analysis Using Gas Chromatography- 
Mass Spectrometry (GC-MS)  
 To examine the potential degradation of ManLAM by PCA treatment, experiments 
were designed to test for the most likely ManLAM hydrolysis products [i.e., fragments 
from the arabinan side chain (scheme 2.1)].26-28, 51, 57-59 For these measurements, ManLAM 
samples were prepared in PBS and divided into two 500 µL fractions; one fraction was 
subjected to PCA treatment and the other to the same processing steps, but PBS was used 
in place of the PCA treatment reagents. The samples were then passed through a 3 kDa 
MWCO filter to separate intact ManLAM from any degradation products. This approach 
separates the degradation products below the 3 kDa cutoff of the filter from those above 
the cutoff and intact ManLAM. In other words, the membrane retains intact ManLAM and 
larger fragments, while the smaller, degraded fractions pass through the membrane. The 
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filtration step was carried out a total of 4 times through a 3 kDa MWCO filter at 1398 g for 
10 min. After the first filtration, the next three filtrations replenished the fluid phase by the 
addition of 200 µL of H2O. The filtrate and the retentate after the final filtration were 
collected separately and lyophilized. 13C5-D-arabinose (1.0 µg) and 3-OMe glucose 
(1.0 µg) were added to each sample as internal standards for arabinose and mannose, 
respectively. 
The alditol acetate derivatization process used for the GC-MS analysis of arabinose 
and mannose, and the method for using the internal standards have been detailed 
elsewhere.26, 57 Briefly, the samples undergo alditol acetate derivatization per the following 
steps: (1) trifluoroacetic acid [(TFA) 2 M] hydrolysis; (2) reduction with NaBH4; and (3) 
acetylation with pyridine and acetic anhydride. The samples were then partitioned between 
water and chloroform, and the organic layer, which contains the derivatized materials, was 
collected. Finally, the samples were dried under high purity N2 and reconstituted in 100 µL 
chloroform (HPLC grade) for analysis by GC-MS. 
GC-MS analyses were carried out using a Varian CP 3800 gas chromatograph 
coupled to a MS320 mass spectrometer fitted with a J&W VF5ms (5% phenyl 
methylpolysiloxane) capillary column (30 m x 0.25 mm x 0.25 µm) column. The oven 
temperature upon injection was held at 100 °C for 1 min, and then ramped at 20 °C/min to 
150 °C, 5 °C/min to 240 °C, and, finally, at 30 °C/min to 300 °C. The arabinose and the 
13C5-arabinose internal standards have characteristic ions at m/z 217 and 220, respectively. 
The quantity of these two compounds was determined from the extracted ion 
chromatogram (EIC). The quantity of the mannose and 3-OMe glucose was determined 
using the total ion chromatogram (TIC). The amounts of arabinose and mannose, both of 
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which are indicative of the amount of ManLAM in a sample, were determined from the 
intensity ratio of the m/z peaks for arabinose and mannose relative to those of 13C5-
arabinose and 3-OMe glucose, respectively. Next, the peak ratios were multiplied by the 
mass of added 13C5-arabinose and 3-OMe glucose, which was 1000 ng for each. To account 
for the higher ion abundance of mannose relative to 3-OMe glucose, the resultant peak 
ratio was divided by a response factor of 1.44. Because ManLAM is composed of ~60% 
arabinose and ~40% mannose, the measured quantities of these two species can be used to 
calculate the original amount of ManLAM in the PCA-treated and untreated sample 
factions.26, 60-61 
 
2.2.6 Patient Sample Cohort 
 Anonymized archived patient serum samples were provided by FIND. These 
samples were collected from adult male and female patients with TB-suspect symptoms 
from clinics in South Africa, Vietnam, and Peru. The samples were separated into serum 
and subsequently frozen (-80° C) shortly after collection. Each sample was analyzed to 
determine HIV and TB status; TB status was based on SSM, bacterial culture and chest x-
ray (if available). For the analysis described herein, 106 total patient samples were analyzed 
with 54 TB-positive and 52 TB-negative based on the results from the bacterial culture 
tests. 
The assay results were analyzed using the methods described in our previous 
works.46, 62 In brief, the patient samples were analyzed in duplicate, due to the small 
volumes available. A patient sample was designated TB-positive if the signal response for 
each duplicate was greater than the limit of detection (LOD) and TB-negative if the 
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response for each duplicate was below the LOD. In the few instances where there was 
disagreement between the replicates for a given patient sample, the sample was marked as 
indeterminate and removed from subsequent analysis. The LOD is the calculated ManLAM 
concentration which produces an absorbance distinguishable from samples devoid of 
ManLAM (blanks) ; LOD is described by equation 2.1. 
 𝐿𝐿𝐿𝐿𝐿𝐿 = 𝐴𝐴𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵 +  3 ∗ 𝜎𝜎𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵 (2.1) 
where ABlank is the average absorbance for the blank samples and σBlank denotes the standard 
deviation from replicate measurements. 
The performance of the assay as a diagnostic tool is described by its clinical 
accuracy.63 Clinical accuracy is defined by two metrics, clinical sensitivity and clinical 
specificity. Clinical sensitivity is a measure of how accurately a diagnostic test correctly 
determines infected patients as being infected, and is defined as the number of true 
positives (TPs) (i.e., correctly identifying an infected patient) divided by the sum of TPs 
plus false negatives (FNs). An FN occurs when a sick patient is determined to be healthy. 
Clinical specificity is a measure of the how accurately a diagnostic test correctly determines 
a healthy patient as being healthy. In this case, the number of true negatives (TNs) (i.e., 
correctly identifying a healthy patient) is divided by the sum of the TNs plus false positives 
(FPs). A false positive is a result that determines a healthy patient as being sick. These 
metrics are expressed as percent in equations 2.2 and 2.3.63 
 
𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 =  𝑇𝑇𝑇𝑇
𝑇𝑇𝑇𝑇 + 𝐹𝐹𝐹𝐹  ×  100 (2.2) 
 
𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 =  𝑇𝑇𝐹𝐹




2.2.7 Ethical Statement 
The anonymized TB-suspect patient samples used herein were provided by FIND 
and collected with informed consent in accordance with the protocols of the Declaration of 
Helsinki. The designated sample numbers used to index the samples are arbitrary and 
cannot be traced back to the patients. The Institutional Review Board at Colorado State 
University approved the study; and, as a pre-existing collection, the Institutional Review 
Board at the University of Utah considered the study described herein exempt from further 
review. None of the authors have access to any identifying patient information. 
 
2.3 Results and Discussion 
2.3.1 Measured ManLAM Recoveries from PCA-Treated  
and Untreated Samples 
 ManLAM was spiked into human serum or into PBS with 1% BSA and then diluted 
with the appropriate diluent to 1000, 500, 100, and 50 pg/mL. Sample blanks consisted of 
stock human serum or PBS with 1% BSA. The serum samples spiked with ManLAM were 
split in half. One half of these samples was PCA treated; the other half of samples used 
serum instead of PCA reagents. The remaining steps were identical for both subsets. The 
samples prepared in PBS with 1% BSA were processed the same way as the PCA-treated 
samples, except PBS with 1% BSA was used in place of the PCA treatment reagents. Due 
to dilution from PCA treatment, the final ManLAM concentrations in the spiked samples 
after the treatment process were 850, 425, 85, and 42.5 pg/mL. 
Figure 2.1 shows the ELISA responses as a function of ManLAM concentration 





Figure 2.1. ELISA dose-response plots for ManLAM spiked into PBS containing 1% 
BSA (black), PCA-treated human serum (red), and whole serum (green). 
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ManLAM concentration for the samples in PBS with 1% BSA and in PCA-treated serum. 
However, the samples analyzed directly from untreated serum show no detectable 
concentration dependence (i.e., all of the responses were statistically indistinguishable 
from that of blank serum the Student’s t-test is applied). The untreated serum responses 
indicate that ManLAM is unable to bind to the capture surface and/or be effectively labeled 
after capture by the tracer antibody. After PCA treatment, however, there is a measurable 
dependence of the response by ELISA to ManLAM concentration. The difference between 
untreated whole serum and treated serum indicates that PCA treatment removes proteins 
that passivate the capture surface, which prevents ManLAM capture, and/or frees 
ManLAM from protein complexation, which enables its capture and labeling.  
 While there is a readily measurable response in the PCA-treated samples, the signal 
strengths are significantly lower than those for the ManLAM samples prepared in PBS with 
1% BSA. In this example, the absorbance after PCA treatment for ManLAM spiked into 
serum at 850 pg/mL is only 28% of that for the sample prepared in PBS with 1% BSA at 
the same spike-in level, indicating suboptimal ManLAM recovery. Furthermore, replicate 
assays (n=5) with each sample concentration performed in triplicate have shown recoveries 
as low as ~10%, which resulted in an average recovery of 22±11% for initial ManLAM 
concentrations between 85 pg/mL and 1.0 ng/mL. The difference in assay performance is 
also evident from the fact that the analytical sensitivity (i.e., slope of the linear least squares 
fitted calibration line) is a factor of ~4 lower in the treated serum samples relative to the 
PBS with 1% BSA samples. Taken together, these results indicate that PCA sample 
treatment significantly improves ManLAM detection over that of untreated serum, but that 
the overall recovery is low, only 22±11%, and highly varied. 
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As noted earlier, the lower response for the PCA-treated samples may be due to 
capture surface passivation and/or the ineffective decomplexation of ManLAM. It is also 
possible that the susceptibility of glycofuranosyl groups to acid hydrolysis26-28, 51 alters the 
structure of ManLAM in a way that degrades the epitope sites used for antibody 
recognition. The next sections investigate the possible contributions of each pathway.  
 
2.3.2 Capture Surface Passivation 
 There are a large number of components in human serum (e.g., proteins, 
carbohydrates, and electrolytes) that can potentially passivate the immobilized capture 
antibodies and, therefore, limit ManLAM capture.64-66 Our previous work showed that the 
total protein content remaining in a serum sample after PCA treatment was 4% (2 mg/mL) 
of that in as-received human serum (55 mg/mL). In other words, there is still a significantly 
higher amount (2 mg/mL) of protein relative to the ManLAM spike-in levels (≤1.0 ng/mL). 
To determine if surface passivation plays a role in the measurement, capture substrates 
were first blocked with PCA-treated serum or with whole serum. A set of substrates was 
also prepared using SB as a comparative reference. The three sets of wells were then 
exposed to ManLAM solutions prepared in PBS containing 1% BSA at concentrations of 
0, 500, and 1000 pg/mL, and the remaining steps of the assay were conducted as described 
previously. 
Figure 2.2 presents the dose-response curves obtained for three sets of samples.  
The plot for the capture surface treated with SB is nearly indistinguishable from that in 
figure 2.1, which demonstrates the level of assay-to-assay reproducibility. In contrast, the 





Figure 2.2. ELISA dose-response plots for capture substrates blocked with SB (black), 
PCA pretreated human serum (red), and untreated human serum (green). ManLAM 
solutions were prepared in PBS containing 1% BSA. 
 
ManLAM Concentration (ng/mL)























a blocker; an average decrease of 24±6% was observed for the 500 and 1000 pg/mL 
samples. Furthermore, the slope of the linear fit line when blocking with whole serum is 
14% lower than that with SB blocking. This difference suggests that one or more 
components present in whole serum interfere with the ability of the capture surface to 
effectively bind ManLAM. These interactions appear to be relatively robust as the effects 
persist through the washing steps performed between the end of blocking and the step to 
capture ManLAM. 
The PCA-treated serum samples, however, follow a response that is almost 
identical to that for ManLAM in PBS with 1% BSA. The analytical sensitivities for the two 
dose-response plots are statistically indistinguishable using a Student’s t-test at a 95% 
confidence interval. This result indicates that, unlike the surface blocked with whole serum, 
the residual materials in the PCA-treated samples do not measurably passivate the surface 
or otherwise interfere with ManLAM capture. We can conclude that surface passivation is 
not a likely contributor to the diminished recovery of ManLAM from the PCA-treated 
serum samples (figure 2.1), and that the reduced signal observed is caused by other factors. 
 
2.3.3 Acid Degradation of ManLAM 
As noted, ManLAM has been found to be susceptible to acid hydrolysis, but the 
extent of the possible cleavage of its arabinose side chains due to PCA treatment has not 
yet been examined in detail.28, 67-68 Preliminary data using a glycan microarray suggest that 
the capture antibody is selective to the arabinan side chains and mannose capping motifs 
(private communication with Todd Lowary, Dept. of Chemistry, University of Alberta, 
June 13, 2017).69 As such, it is possible that any structural degradation of ManLAM could 
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lead to decreased ManLAM-antibody affinity, resulting in a lower ELISA signal, as 
observed in figure 2.1.70  
To determine if the PCA treatment process alters the structure of ManLAM, 
carbohydrate analysis by GC-MS was performed on as-prepared and PCA-treated samples 
of ManLAM spiked into PBS. These samples were prepared in PBS devoid of BSA to 
eliminate protein content as a variable and to avoid the endogenous arabinose found in 
human serum (private communication with Prithwiraj De, Colorado State University, July 
9, 2017). Our discussion of the analysis will assume that intact ManLAM remains in the 
retentate during the filtration step and that degradation products from acid hydrolysis pass 
through the filter (see section 2.2.5). By measuring the total arabinose and mannose content 
in all four sets of samples and by recognizing that ManLAM is composed of ~60% 
arabinose and ~40% mannose by weight, it is therefore possible to determine the total 
amount of ManLAM originally present in the sample and to qualitatively determine if PCA 
treatment degrades ManLAM. The typical sample recovery and LOD (absolute mass) for 
this method is ~95% and 500 pg, respectively.  
 The results from the GC-MS analysis are summarized in table 2.1, which includes 
the measured amounts of arabinose and mannose in the filtrate and retentate for the PCA-
treated and untreated samples. The quantities of arabinose and mannose were used to 
calculate the initial amount of ManLAM in the samples. For the untreated samples, there 
was no detectable amount of arabinose or mannose in the filtrate, indicating that, in the 
absence of PCA-treatment, the structure of ManLAM is unaltered by the other solution 
processing steps. 
 The results for the PCA treated samples are markedly different. Arabinose is  
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Table 2.1. GC-MS results for samples of ManLAM prepared in PBS buffer with and 
without subsequent PCA treatment. 
 Untreated Samples PCA-treated Samples 
 Retentate (ng) Filtrate (ng) 
Retentate 
(ng)  Filtrate (ng)  
Arabinose  12.6±3.9†   ND* 5.2±0.2 8.6±2.1 
Calculated ManLAM 
from Arabinose  21.0±6.5  ND 8.7±0.3 14.1±2.1 
     
Mannose 9.2±4.5 ND 9.0±0.3 ND 
Calculated ManLAM 
from Mannose 23.0±11.2  ND 22.5±0.8 ND 
*ND: Not detectable (i.e., sample contains <500 pg). 




detectable in both the filtrate and retentate, whereas mannose is only measurable in the 
retentate. A little more than 60% (8.6±2.1 ng) of the total measured arabinose in the PCA-
treated samples is found in the filtrate; the remaining 40% (5.2±0.2 ng) is in the retentate. 
This indicates that a significant portion of the arabinose groups in the side chains are 
cleaved during the PCA treatment process. The cleaved arabinose groups are most likely 
initially a mixture of monosaccharides and short (n=2 or 3) polysaccharides from the 
terminal ends of the side chains, which are further degraded to monosaccharides by TFA 
during the alditol acetate derivatization process.27-28, 57-59 Unlike arabinose, mannose is only 
detected in the retentate of both the PCA treated and untreated samples, 9.0±0.3 and 
9.2±4.5 ng, respectively. This indicates that the core mannan structure of ManLAM 
remains intact during the PCA treatment process and that the only detectable structural 
degradation occurs in the arabinan side chains.  
Based on the measured arabinose and mannose content, the calculated amounts of 
intact ManLAM in the retentate of the untreated samples were 21.0±6.5 ng and 23.0±11.2 
ng, respectively. The calculated intact ManLAM content in the retentate and filtrate of the 
PCA samples was 8.7±0.3 ng and 14.4±2.1 ng, respectively, based on the measured 
arabinose content. The ManLAM content determined from the total arabinose detected in 
both the filtrate and retentate was 23.1±1.9 ng. This is in good agreement with the 
calculated total ManLAM content, 22.5±0.8 ng, based on the measured mannose found in 
the retentate. The agreement of the mass of mannose and arabinose in the treated and 
untreated samples confirms the reliability of the GC-MS analysis.  
To determine the effect of degradation on the ELISA measurements, a set of 
ManLAM dilutions were prepared in PBS and split into two equal volume fractions. Like  
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the GC-MS experiments, one set of fractions underwent PCA treatment and the other used 
PBS in place of the PCA treatment reagents. All remaining solution handling steps were 
the same for both fractions. These samples were prepared without BSA to remain 
consistent with the samples used for the GC-MS experiments. The ELISA dose-response  
plots from these measurements are presented in figure 2.3. The responses from the samples 
subjected to PCA treatment are significantly less than those from the untreated samples. In 
this case, PCA- treated ManLAM in PBS, samples have ~23% reduction in signal 
sensitivity compared to the untreated samples. However, replicate assays (n=5) have shown 
a loss of as much as 40% at ManLAM concentrations ≥ 42.5 pg/mL with an average of 
26±10%, highlighting how the extent of ManLAM degradation may impact 
immunorecognition with the antibodies on the underlying capture surface. 
 Interestingly, the difference in the ELISA sample sets differs from the analogous 
results for the GC-MS analysis. The GC-MS data indicated that ~60% of the ManLAM 
was degraded by PCA treatment to a level sufficient to pass through a 3 kDa MWCO filter. 
While the implications are not yet clear, these results suggest that the assay detects a portion 
of the degraded ManLAM, most likely part of the degraded fraction remaining in the 
retentate. The ELISA results also support the conclusion that the degradation of ManLAM 
occurs primarily at the arabinose side chains because the capture antibody in particular 
recognizes structural elements on the side chain, rather than at the mannan core. Therefore, 
changes to the side chain structure would result in a reduction of the antibody binding 
affinity. The next section examines the contribution of decomplexation efficiency to the 





Figure 2.3. ELISA response for ManLAM spiked into PBS and for ManLAM spiked into 
PBS and then subjected to PCA treatment.  
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2.3.4 Extent of Decomplexation 
In an effort to identify other possible cause(s) for reduced ManLAM recovery, we 
investigated another possible approach to disrupt ManLAM complexation without 
inducing ManLAM degradation. Serine proteases such as trypsin and PK are workhorses 
used for purifying a target from proteinaceous material and the isolation of DNA and 
RNA.15, 71-73 PK is a nonspecific, broad spectrum, serine protease that targets only proteins 
and can effectively degrade proteins to short chain polypeptides (n≥4).71-73 Following an 
established PK treatment, this section investigates the use of PK to break up ManLAM- 
protein complexation without inducing the ManLAM degradation observed in the PCA 
treatment procedure.74 For this, ManLAM was spiked into whole serum and 10 mM PBS 
with 1% BSA from 42.5 pg/mL to 1.0 ng/mL plus a blank (0 pg/mL), and analyzed by 
ELISA. Portions of the samples prepared in whole serum were also PCA or PK treated 
before running ELISA. The as-is PBS with 1% BSA samples were used as the comparator 
for calculating ManLAM recovery factors.  
 As shown in figure 2.4, the ManLAM recovery is significantly larger when treated 
with PK compared to PCA. The recovery using PK treatment is 47±7% compared to 
22±11% using PCA treatment. In figure 2.1, there is a ~65% loss of signal in the PCA 
pretreated samples; however, the loss is highly varied, indicating the importance of further 
characterizing the extent of ManLAM degradation as it relates to detection by 
immunorecognition. Taken together, the ELISA (figure 2.3) and the GC-MS results 
indicate the degradation of ManLAM accounts for 40-60% of the lost signal in figure 2.1. 
We therefore believe that the remaining ~10-25% of reduced signal is the result of 






Figure 2.4. ManLAM recovery as a function of treatment type, normalized to response 
of ManLAM in PBS containing 1% BSA. On average, the samples treated with the 
proteinase K treatment method show a ~2x improvement (47±7% compared to 22±11%) 
in ManLAM recovery relative to PCA treatment. The average and standard deviations 
arise from averaging the calculated recovery for ManLAM spiked into serum and buffer 
samples from 85 pg/mL to 1.0 ng/mL for 5 PCA treatment assays and 3 proteinase K 
treatment assays, each run as triplicates. 
 




















digestion, which are beginning to show higher levels of ManLAM recovery, are consistent 
with this viewpoint. These results show that the search for an ideal treatment method has 
begun to bear fruit, but there appears to be room for improvement. To assess how these 
findings affect the clinical accuracy of a TB diagnostic test, the next section describes the 
analysis of a small set of patient samples that were TB-positive or TB-suspect, but 
ultimately negative by SSM and bacterial culture. 
 
2.3.5 Impact of ManLAM Recovery on Clinical Accuracy 
To test the impact of the higher level of ManLAM recovery found with PK 
treatment, comparative ELISA measurements were run on 106 TB-positive and TB- 
negative patient serum samples that were provided by FIND. Of the 106 patient samples, 
57 were PCA treated and 49 were PK treated. Figure 2.5 summarizes the clinical accuracy 
results, as determined by our ELISA procedure, from the PCA-and PK-treated patient 
samples. The small volumes of each sample precluded side-by-side analysis using both 
PCA and PK treatment methods.  
The results in figure 2.5 show that the clinical sensitivity of samples treated with 
PK are significantly greater by ~20% than that of the PCA treated samples, 77% of PK 
compared with 57% for PCA. This result supports the viewpoint that the improved signal 
recovery shown in figure 2.4 for the PK treatment method results in a notable improvement 
in clinical sensitivity. If ManLAM is liberated to a greater extent and without apparent 
degradation, TB-positive patients can be diagnosed using ManLAM as a marker with a 
higher degree of accuracy. 





Figure 2.5. Clinical accuracy presented as percent sensitivity and specificity for patient 
samples analyzed by ELISA for ManLAM content after either PCA or PK treatment. 
Treatment with proteinase K improves the clinical sensitivity increases by ~20 % while the 




























treated samples (70% for PK compared to 68% for PCA). However, both methods 
measured ManLAM in some of the culture-negative samples, resulting in FPs. This may 
be due to the nonspecific adsorption of endogenous proteins present in the patient samples 
after treatment, but not in the control serum, which cross reacts with the labels, leading to 
unexpectedly high signals. It is important to note that all of the patient samples were from 
TB-suspect individuals, meaning that they were collected from patients presenting 
symptoms consistent with active TB infection in regions of the world where TB is endemic. 
We suspect a small fraction of the culture-negative samples may be missed by culture for 
two reasons.  
First, a large number of individuals in the regions where the samples were collected 
are very likely to be latently infected with TB; in other words they are infected with TB 
bacilli, but are not actively infected.1, 75 These patients would be negative from the SSM 
and bacterial culture test, but may have some level of bacterial loading in their bloodstream, 
leading to a measurable response in our assay and a positive diagnosis. Furthermore, ~10% 
of all TB infections are extrapulmonary. That is, Mtb enters the bloodstream and develops 
into active infections in the lymphatic system, larynx, spine, bone, or kidneys.1, 76-79 Indeed, 
reports have shown that nonpulmonary manifestations of the disease cannot be detected by 
sputum sampling.1, 8-11 Serum, to the contrary, is a reservoir of the products produced 
throughout the body, and several of the FPs for the detection of ManLAM are at levels well 
above the measurable LOD with either treatment method. To test these suspicions, a more 
in depth set of studies are needed which should also focus on nucleic acid amplification 





This work investigated the utility of PCA and PK treatment methods as a means to 
liberate ManLAM from complexation in human serum and, therefore, enhance its detection 
as a marker of active TB infection. Using either treatment method, the recovery of 
ManLAM is not quantitative (i.e., >99.9%), but is significantly higher with PK compared 
to PCA. The effect of ManLAM recovery on the clinical accuracy of an ELISA test was 
also explored, using a small pilot set of patient samples in order to determine the 
relationship between recovery levels and clinical accuracy. Not surprisingly, higher levels 
of ManLAM using the PK treatment method resulted in a clear (~20%) improvement in 
the clinical sensitivity to 77%. Experiments aimed at optimizing the recovery of ManLAM 
with PK treatment are underway and we are working to establish linkages to serum 
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VERSATILE APPROACH TO TUBERCULOSIS BIOMARKER DETECTION BY 
SURFACE-ENHANCED RESONANCE RAMAN SCATTERING 
 
3.1 Introduction 
Recent years have seen sharp growth in the use of surface-enhanced Raman 
scattering (SERS), with gold, silver, and a few other types of nanoparticles (NPs), as a 
detection methodology in immunoassays, as well as in a number of other bioanalysis 
areas.1-3 Because the electromagnetic enhancement mechanism of SERS is sensitive to the 
size, composition, and degree of aggregation of these materials, and to the dielectric 
properties of the local environment, the development of an extensible, robust, and 
reproducible measurement is an immense challenge.3-9 To address the challenges 
associated with improving the usability of SERS as an analytical technique, a number of 
research groups have developed highly ordered nanometric substrates (e.g., 2-dimensional 
nanoparticle arrays, inverse opal structures, and nanolithographically produced 
3-dimensional arrays such as pyramidal structures) to produce tunable and consistent 
enhancement factors.10-12  
These nanofabricated SERS-enhancing substrates, however, suffer from several 
technical challenges.13-16 First, fabricating these surfaces requires a high degree of technical 
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expertise and precise patterning hardware, and as such, can be a difficult and costly 
endeavor. Nanofabricated surfaces can also be affected in post processes, such as dicing 
and chemical etching. These processes can alter the carefully crafted surface structures and 
thus change the intended plasmonic properties.13-16 Finally, forming surfaces with long-
range order (e.g., millimeters or centimeters) challenges the capabilities of current 
fabrication techniques.13-16  
Herein, we seek to demonstrate how a chemically fabricated SERS-enhancing 
substrate can be used to increase the sensitivity of disease biomarker detection without the 
use of patterning processes. The basis for this enhancing surface arises from combining the 
enhancement effects typically associated with SERS with those of resonance Raman 
spectroscopy (RRS) in a phenomenon described as surface-enhanced resonance Raman 
spectroscopy (SERRS). With SERRS, the incoming excitation wavelength induces an 
electronic transition in the Ramanophore adsorbed on the gold substrate, which in this case 
is a layer of chemically modified cyanine 5 (Cy5).12, 17-18 With SERS, large signal 
amplification arises from an electromagnetic enhancement mechanism due to the induction 
of localized surface plasmons in nanometric coinage metals (i.e., gold and silver).6, 8, 19  
Work previously performed in our laboratory centered on the optimization of 
relevant parameters, such as the use of gold nanoparticles with a tight size dispersity, 
reliable chemical functionalization, and the plasmonic interactions with the underlying 
gold surface, such that an enhancement factor of ~106 can be reproducibly obtained in an 
immunoassay using SERS.20-22 Distinct from SERS, the enhancement mechanism 
associated with RRS and by extension, SERRS, arises when the excitation wavelength used 
during the measurement coincides with an electronic transition within the Ramanophore, 
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which increases the Raman scattering intensity by as much as another factor of 106.12, 18 
Previous work has realized single molecule detection using SERRS due to the 
multiplicative effects of electromagnetic and electronic enhancements to achieve reported 
enhancement factors as high as ~1014.12, 23 This Chapter details the fabrication and 
characterization of an enhancing substrate for a SERRS immunoassay. For this, a gold 
substrate is functionalized with a thiolated Cy5 adlayer, which has an electronic transition 
coinciding with the wavelength of the excitation source at 633 nm. An evaluation of this 
novel approach to immunoassays with respect to the sensitive detection of a disease 
biomarker indicative of active tuberculosis (TB) infection is also presented.  
According to a recent report by the World Health Organization (WHO), it is 
estimated that 9.6 M people developed active TB infections in 2015, of which roughly one 
third were undiagnosed.24 The cause for such a high level of undiagnosed patients largely 
reflects the difficulties in implementing existing testing methodologies (i.e., sputum smear 
microscopy (SSM) and bacterial culture) in a point-of-need (PON) setting.24-28 The current 
bacterial culture TB test requires a well-developed in vitro diagnostic laboratory 
infrastructure and skilled technicians and physicians to perform the test, has a long 
turnaround time, and is not capable of diagnosing extrapulmonary TB.27, 29-30  
The challenges associated with developing an effective diagnostic approach for TB 
has caused a resurgence in developing tests to detect primary antigenic markers indicative 
of active infections. We recently described the development of a SERS immunoassay for 
the detection of mannose-capped lipoarabinomannan (ManLAM), a 17.3±5 kDa lipoglycan 
found in the cell wall of the M. tuberculosis bacteria.31-34 Although the exact degree of 
branching is varied, ManLAM generally consists of a phosphatidylinositol mannoside 
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anchor linked with a mannose-capped region via an arabinomannan backbone (figure 
3.1).31, 34-36 We have also recently described how the incorporation of new handheld Raman 
spectrometers in the measurement hardware has the potential to facilitate the transition of 
this work from the research laboratory to a truly field-deployable platform by reducing the 
resource burden caused by complex and costly benchtop instrumentation (manuscript in 
preparation and Chapter 4). This Chapter continues to expand on this body of work by 
demonstrating the potential application of the SERRS immunoassay to quantitate levels of 
ManLAM in human serum. The potential utility of this new methodology in PON testing 




 Phosphate-buffered saline (PBS) packs (10 mM with 150 mM NaCl), borate buffer 
(BB) packs (50 mM), and dithiobis (succinimidyl propionate) (DSP) were purchased from 
Thermo Scientific. All buffers were prepared with 18.2 MΩ H2O purified by a Barnstead 
ultrapure water system. Tween 20 (T20), StartingBlock™, 70% perchloric acid (PCA), 
potassium carbonate, and sodium chloride were obtained from Fisher Scientific. Bovine 
serum albumin (BSA), acetonitrile, and dimethyl sulfoxide were purchased from Sigma 
Aldrich. Octadecanethiol (ODT) and 2-aminoethanethiol (AET) were acquired from 
FLUKA. Deuterated 1-octadecane-d37-thiol was obtained from C/D/N Isotopes. 
Polystyrene 24-well microplates and a two-component polydimethylsiloxane (PDMS) kit 
were purchased from Dow Corning. Solid PDMS transfer templates were made following 





Figure 3.1. Generalized structure of lipoarabinomannan (LAM): (1) phosphatidylinositol 
mannoside (PIM2) anchor, (2) mannan core, (3) arabinan side chains, and (4) capping 
motifs. The branching, capping agents, and overall molecular weight vary somewhat 
across different mycobacteria. Mannose-capped LAM (ManLAM) from M. tuberculosis 





Norland and used per packaging instructions. Gold colloids (60 nm diameter, stock 
concentration of ~2 x1010 particles/mL) were acquired from BBI. Ethanol (200 proof) was 
purchased from Deacon Labs. Pooled AB human male serum, hereafter referred to as 
human serum, was obtained from Innovative Diagnostics, Inc. Mechanical-grade silicon 
wafers <1,1,1> were acquired from University Wafer. Gold shot (99.995% pure) was 
purchased from Alfa Aeser. Chrome-plated (99.9%) tungsten rods were acquired from Kurt 
J. Lesker Company.  
The n-hydroxysuccinimide (NHS) ester of Cy5 was obtained from Lumiprobe and 
thiolated with AET following a procedure described elsewhere.38-39 Glass microscope 
slides were purchased from Fisher Scientific and cut to 1x1 cm glass squares. The Raman 
reporter molecule (RRM), 5,5’-dithiobis (succinimidyl-2-nitrobenzoate) abbreviated as 
DSNB, was synthesized following procedures detailed elsewhere.21 A polyclonal rabbit 
antibody for M. tuberculosis (Cat. No. 4601) was acquired from Virostat and used as the 
capture antibody. A monoclonal antibody specific to ManLAM (A194-01), was provided 
by Dr. Abraham Pinter at Rutgers University and used to selectively tag the capture 
ManLAM (see below). ManLAM was isolated and purified by Dr. Delphi Chatterjee at 
Colorado State University.40-41 
 
3.2.2 Materials Fabrication and Sandwich Immunoassay Procedure 
 The general procedures for fabrication and functionalization of the substrates, 
extrinsic Raman labels (ERLs), and the sandwich immunoassay procedure, as overviewed 
in scheme 3.1, have been described in detail elsewhere.2, 21, 42 In brief, template-stripped 





Scheme 3.1. Depicts the preparation of the extrinsic Raman labels (ERLs) and the active 
capture substrate, which are both prepared prior to performing the sandwich 
immunoassay for SERS readout. In brief, a sample is assayed for ManLAM content 
through sequential exposure to the capture substrate, followed by labeling with an ERL 
solution. The resulting nanoparticle-based sandwich is dried under ambient laboratory 
conditions and analyzed using a Raman microscope. The intensity of the signal arising 
from the Raman reporter molecule (RRM) on the ERL surface of the particle is used to 





silicon wafer with a 180-200 nm gold film using resistive evaporation at ≤ 0.1 nm/s. After 
cooling to room temperature, the wafers were removed from the evaporator and clean 
1x1x0.1 cm glass squares were affixed to the surface using a UV-curable optical adhesive. 
The adhesive was cured with UV light for 3 h. Before use, the TSG substrates were 
carefully removed from the Si wafer, exposing the smooth gold film on the bottom side of 
the glass surface. Similarly, 25x75 mm glass microscope slides were coated with a ~200 
nm gold film (10 nm chromium adhesion layer) at ≤0.1 nm/s.43 
The clean gold surfaces were subsequently functionalized with a hydrophobic ODT 
adlayer by contact printing with a PDMS stamp that has a centered 2 mm hole. These 
stamps were immersed in an ethanolic solution of 1.0 mM ODT for 45 s, rinsed with 
ethanol, and dried with high purity nitrogen. The stamp was subsequently pressed onto the 
gold surface, creating a 2 mm diameter address of unmodified gold, surrounded by an ODT 
adlayer. This hydrophobic barrier defines the size of the capture address. Upon removing 
the PDMS stamp, the substrate was rinsed with EtOH and immersed in a 0.1 mM ethanolic 
DSP solution for 16 h. Finally, the samples were removed from the DSP solution, rinsed 
with EtOH, and dried with a stream of high purity nitrogen. 
In the next step, substrates were individually arranged in the wells of a 24-well 
microplate. The substrates were functionalized by the addition of a 20 µL droplet of 10 
µg/mL polyclonal anti-TB antibody (10 mM PBS) and then loaded into a humidity 
chamber. The humidity chamber was sealed and the antibody binding step proceeded for 
60 min. After incubating, the substrates were rinsed with 10 mM PBS with 0.1% v/v Tween 
20 (PBST), blocked with a 20 µL droplet of StartingBlock,™ and sealed in a humidity 
chamber for 60 min. The substrates were subsequently rinsed with 10 mM PBST and 
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exposed to antigen-containing solution (i.e., 20 µL droplets of ManLAM spiked into either 
10 mM PBS with 1% BSA (w/v) or human serum that subsequently underwent acid 
treatment), and the substrates were loaded in a humidity chamber and allowed to incubate 
for 3 h. To remove unbound or nonspecifically adsorbed antigen from the surface, the 
samples were rinsed with 2 mM BB with 0.1% v/v Tween 20 (BBT) with 150 mM NaCl, 
after which a 20 µL droplet of the ERL suspension was applied to each sample. As before, 
the samples were inverted in the humidity chamber and allowed to incubate overnight 
(~16 h). Finally, the unbound and nonspecifically adsorbed ERLs were rinsed from the 
surface with 2 mM BBT with 10 mM NaCl and allowed to dry under ambient laboratory 
conditions prior to Raman analysis.  
The preparation of SERRS assay substrates, as shown in scheme 3.2, and assay 
procedure follow the same general outline as described above. However, the ODT-
addressed TSG substrates were immersed in a 50 µM ethanolic thiol solution comprised of 
a 1:1 ratio of thiolated Cy5 and DSP as opposed to an ethanolic solution of only DSP. This 
result in the resonant Ramanophore forming an adlayer on the underlying gold substrate 
used in the assay. Further characterizations of the as-formed adlayers are described in 
section 3.3.1. 
 
3.2.3 Preparation of Extrinsic Raman Labels 
 In the SERS immunoassay, the ERLs have two main functions: (1) to yield an 
intense Raman spectrum when irradiated with a suitable excitation source, and (2) to impart 
immunospecificity for the target biomarker.2, 20-21 In the SERRS immunoassay presented 





Scheme 3.2. Idealized scheme depicting the modification of a SERS assay (scheme 3.1) 
with the inclusion of a resonant Raman dye, thiolated cyanine 5, to make a surface-




functionalization with a molecular recognition element, and also serve to enhance the 
signal of the resonance dye on the underlying assay substrate through plasmonic 
interactions when tagging the captured target. 
The details concerning the reproducible preparation of ERLs have been described 
elsewhere.2, 20-21 In brief, 1 mL of 60 nm gold colloids was combined with 40 µL of 50 mM 
BB to adjust the pH to 8.5; this suspension was then mixed with 13.7 µL of a 1.0 mM thiol 
solution DSNB in ACN. This solution was mixed through inversion for 30 s and then stored 
in a refrigerator at 2-8˚C for 90 min. Immunospecificity was imparted to the ERL through 
addition of 13.7 µL of a 100 µg/mL solution of the monoclonal A194-01 antibody in 10 
mM PBS. This solution was briefly mixed by inversion for 30 s and stored at 2-8˚C for 90 
min. The next step added 100 µL of a 10% BSA (w/v) solution in 2 mM BB at pH 8.5, 
which promoted colloidal stability and blocked unreacted binding sites. The ERL 
suspension was again mixed by inversion and stored at 2-8˚C for an additional 60 min. To 
remove excess functionalization reagents, the particles were centrifuged 3x for 10 min each 
at ~2000 g. The colorless supernatant was carefully removed from the ERL pellet after 
each centrifugation and the ERLs were re-suspended 2x with 1 mL of 1% BSA (w/v) in 2 
mM BB at pH 8.5. The final resuspension concentrated the ERLs using 250 µL of 2% BSA 
(w/v) solution in 2 mM BB at pH 8.5. Finally, 25 µL of 10% NaCl (w/v) in H2O was added 
to facilitate the colloidal stability. 
 
3.2.4 Sample Treatment  
 Recent work has touched on the interactions that occur between ManLAM and 
endogenous serum proteins when spiked into human serum.44-45 As such, ManLAM 
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samples prepared in human serum require a treatment step to release this marker for 
detection.44 In brief, samples containing ManLAM were acidified to pH ~1 by the addition 
of 70% PCA. This process disrupts the complexed ManLAM by protein denaturation. Each 
sample was vortexed for 10 s and centrifuged at 12,000 g for 5 min to pellet the denatured 
proteins. After this step, the clear supernatant containing the liberated ManLAM was 
transferred to a separate microcentrifuge tube and neutralized to pH 7.5 by the addition of 
2.0 M K2CO3. Finally, the samples were refrigerated at 2-8 º C for 60 min to precipitate 
KClO4. For each sample, the clear ManLAM containing supernatant was transferred to a 
new microcentrifuge tube and the solutions were equilibrated to ambient laboratory 
conditions prior to running the assay. 
 
3.2.5 Raman Scattering Analysis  
 The Raman spectra were collected using a Thermo Scientific DXR Raman 
microscope. The microscope was equipped with a HeNe laser (633 nm) with a measured 
power of 3.03±0.01 mW and a 50 mm slit aperture to the spectrograph. The samples were 
analyzed with 10x objective (numerical aperture of 0.25). The measured focal area of the 
laser on the sample surface was ~69 µm2 giving a power density of ~0.04 mW/µm2. Each 
spectrum was collected using a 0.3 s exposure time, and 3 exposures were averaged per 
spectrum. A total of 25 spectra with a uniform offset spacing of 125 µm were collected per 
sample, near the center of the address. For SERS, quantitation used the average peak height 
of the symmetric nitro stretch, νs(NO2), of DSNB at 1336 cm-1. For SERRS the peak for 
the polymethine bridge stretch, ν(C─C─C), of Cy5 at ~560 cm-1, was used.20, 46-48 For the 
adlayer characterizations (section 3.3.1) the laser power was increased to 7.02±0.01 mW 
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and the integration time was changed to 30 s. 
 
3.2.6 Infrared Spectroscopy Analysis 
 Infrared external reflection spectra (IR-ERS) of the spontaneously adsorbed 
adlayers were collected using a modified Nicolet Magna 850 Fourier transform 
spectrometer equipped with a liquid nitrogen (LN2)-cooled mercury cadmium telluride 
detector. Samples were prepared by immersion of gold-coated microscope slides in 
ethanolic solutions of DSP, 1:1 DSP:Cy5-SH (mole fraction), and Cy5-SH for 16 h. Spectra 
were collected using p-polarized light at an incident angle of 82° in a nitrogen atmosphere, 
and each spectrum was collected with a resolution of 4 cm-1 by co-adding 1024 scans of 






where R is the sample spectrum and R0 is the spectrum of a deuterated octadecanethiol-d37 
reference sample.43, 49  
 
3.2.7 Scanning Electron Microscopy (SEM) Analysis 
 Scanning electron microscopy (SEM) imaging was used to determine ERL surface 
densities on the completed assay substrates. Images were collected using a Hitachi S-4800 
field emission scanning electron microscope. Each substrate was affixed to an SEM 
specimen mount to facilitate SEM analysis. The substrates were imaged 5 times at 
randomly selected locations about the address center. The images were taken at an 
acceleration voltage of 5 kV. Image J software (National Institutes of Health, Bethesda, 
MD) was used to analyze images and to enumerate particle density.  
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3.2.8 Data Analysis and Analytical Figures of Merit 
Analytical sensitivity is used to gauge the performance of the two immunoassay 
formats, and is defined in two ways. First, analytical sensitivity can be categorized in terms 
of the limit of detection (LOD) (i.e., the lowest concentration of ManLAM that produces 
an instrument response which is statistically different from a blank sample).3, 50 Analytical 
sensitivity can also be described as the ability of the assay to resolve different 
concentrations of ManLAM (i.e., an increase in sensitivity corresponds to an increase in 
the change in signal between different ManLAM concentrations).51 The limit of the blank 
(LOB) and LOD are defined following the guidelines outlined by the Clinical and 
Laboratory Standards Institute, in the equations 3.2 and 3.3.50, 52-53 
 𝐿𝐿𝐿𝐿𝐿𝐿 = 𝐼𝐼𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵  +  1.645 ×  𝜎𝜎𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵 (3.2) 
 𝐿𝐿𝐿𝐿𝐿𝐿 = 𝐿𝐿𝐿𝐿𝐿𝐿 +  1.645 ×  𝜎𝜎𝑥𝑥  (3.3) 
where IBlank is the average signal of replicate blank measurements, σBlank is the standard 
deviation of the blank measurements, and σx is the standard deviation of the replicate 
measurements for the first sample that has an average measurement distinguishable from 
the blank at a 95% confidence interval. The LOB and LOD are converted from Raman 
signal in cts s-1 to concentration by dividing by the slope ((cts s-1)/(ng/mL)) of the fit line 
determined from the dose-response plot. The second definition of analytical sensitivity, 
concentration resolving power or the ability to differentiate separate ManLAM 
concentrations, can be described in two ways: (1) the slope of the linear fit line from dose-
response plots of ManLAM, and (2) the signal-to-blank ratio (SBR) at a specified analyte 




3.3 Results and Discussion 
The following sections describe the results of a series of experiments designed to 
characterize the formation of the thiolated-Cy5 adlayer and to determine the performance 
of a SERRS substrate when applied to the detection of ManLAM, a biomarker indicative 
of active TB infection. These sections describe (1) the characterization of DSP, mixed 
DSP:Cy5-SH, and Cy5-SH adlayers on gold using IR-ERS and Raman scattering; (2) the 
effectiveness of the SERRS substrate in the detection of ManLAM and the potential for its 
broader application in disease diagnostics; (3) an in-depth analysis using SEM and Raman 
scattering to assess the basis of the improvements in ManLAM detection; and (4) a 
discussion of possible approaches to further improve the use of this methodology.  
 
3.3.1 Characterization of Cy5-based Enhancing Surface 
 This section describes the characterization of the three adlayers by IR-ERS and 
Raman scattering. Figure 3.2 presents the resulting IR-ERS spectra from 900 to 1900 cm-1. 
Band assignments are listed in table 3.1. Spectral features indicative of the terminal NHS 
group are particularly apparent for the DSP-based adlayer.43 These include the carbonyl 
stretch, ν(C=O), of the ester linkage at 1812 cm-1, the symmetric carbonyl stretch, νs(C=O), 
at 1785 cm-1, and the asymmetric carbonyl stretch, νa(C=O), at 1747 cm-1 of the NHS 
group.43, 54 Other features consistent with the adlayer composition include the symmetric 
CNC stretch, νs(C-N-C), at 1372 cm-1, the asymmetric CNC stretch, νa(C-N-C), at 
1216 cm-1, and the C-O stretch, ν(N-C-O), at 1082 cm-1.43, 54 There are, in comparison, only 
a few distinct bands present in the spectra to differentiate the two Cy5-containing 





Figure 3.2. Infrared external reflection spectra for planar gold substrates functionalized 











Table 3.1. Infrared band assignments and peak positions for gold substrates coated using 
ethanolic solutions of DSP, 1:1 DSP:Cy5-SH (mole fractions), and Cy5-SH.43, 54-56 
 
Mode 
Assignment Description Peak Position (cm
-1) 
  DSP DSP:Cy5-SH Cy5-SH 
ν(C═O) carbonyl stretch of ester 1812 ‒ ‒ 
νs(C═O) NHS symmetric carbonyl stretch 1785 ‒ ‒ 
νa(C═O) NHS asymmetric carbonyl stretch 1747 1739 1737 
δ(CH2) methylene scissors 1467 and 1429 1467 1467 
δ(CH2) and 
ν(C═C) 
methylene scissors and ring 
modes ‒ 1467-1460 
1467-
1460 
νs(C─N─C) NHS symmetric CNC stretch 1372 1363 1369 
νa(C─N─C) NHS asymmetric CNC stretch 1216 ‒ ‒ 






the asymmetric carbonyl stretch in the DSP:Cy5-SH adlayer, indicating that there is very 
little, if any, of the DSP present in this adlayer. The absence of bands clearly assignable to 
the modes of Cy5 in either spectrum point to the likelihood that the thiolated Cy5 molecules 
in the adlayer are chemisorbed with the extended aromatic ring structure in the plane of the 
gold surface.56 
Figure 3.3 shows Raman spectra for the mixed and thiolated-Cy5 adlayer samples. 
The DSP adlayer was indistinguishable from that of an uncoated substrate. Table 3.2 lists 
the band assignments for the vibrational modes of the two adlayers.48, 55, 57-58 The two 
spectra confirm the formation of the expected adlayers (e.g., the aromatic ring stretches at 
1598 cm-1, 1355 cm-1, 935 cm-1, 800 cm-1) and the C-C-C stretch of the polymethine bridge 
at 560 cm-1. Both spectra also have a band at ~320 cm-1, which is assigned to the gold 
thiolate stretching mode, ν(Au-S), which is consistent with the expected chemisorption of 
aromatic thiols on gold.59-60 More so, and in agreement with the IR-ERS measurements, 
the intensity of the Raman spectra of the two coatings are roughly the same, indicating 
there is very little, if any, DSP present in the mixed adlayer. 
An example of the spectral responses for the immunoassays based on both SERS 
and SERRS for ManLAM (50 ng/mL) spiked into human serum and then PCA treated, is 
presented in figure 3.4. The SERS response is composed of only features due to the DSNB 
adlayer formed on the ERL used to tag captured ManLAM. The band assignments for these 
features are listed in table 3.2. The most prominent Raman bands include the symmetric 
nitro stretch, νs(NO2), at 1336 cm-1, and the aromatic ring breathing modes, ν(C─C), at 
1556 cm-1.21 A very weak ν(Au-S) band at 320 cm-1 is also present.59-60 The baseline-





Figure 3.3. Raman spectra for samples prepared using ethanolic solutions of 1:1 
DSP:Cy5-SH (mole fraction) and Cy5-SH that was coated on smooth gold substrates. 
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Table 3.2. Raman band assignments and peak positions for the Ramanophores, Cy5-SH 
and DSNB, used in the SERRS and SERS immunoassays.48, 55, 57-60 
 
Mode 
Assignment Description Peak Position (cm
-1) 




C-N stretch overlapped with 
aromatic ring vibrations 1598 ‒ 
ν(C─C) 
Breathing aromatic ring modes ‒ 1566 
ν(C═C) aromatic ring vibrations (broad) 1470 ‒ 
ν(C─C─C) polymethine bridge stretch 1405 ‒ 
ν(C─C) and 
δ(C─H) 
aromatic ring modes 
overlapped with C-H 
bending 
1355  
νs(NO2) symmetric nitro stretch ‒ 1336 
ν(C─C) aromatic ring modes 1306  
ν(C─N) quinoline stretch 1271  ‒ 
δ(C─H) in plane bend 1236, 1149 and 1123 ‒ 
ν(C─N─O) and 
ring modes 
succinimidyl NCO stretch 
and aromatic ring modes ‒ 1079 
ν(C─C) ring vibrations (broad) 1022, 935, 800 ‒ 
δ(NO2) nitro scissoring  851 
δ(C─H) out-of-plane bend 644 ‒ 
ν(C─C─C) polymethine bridge stretch 560 ‒ 






Figure 3.4. Raman spectra collected from 50 ng/mL ManLAM spiked in human serum, 
which has been subsequently pretreated. The top is a spectrum for the surfaced-enhanced 
resonance Raman scattering (SERRS) assay (Cy5-SH functionalized substrate) sample, 
and the bottom spectrum is for the surface-enhanced Raman scattering (SERS) assay 
(DSNB-modified particles) sample. The peak heights of the 560 cm-1 and 1336 cm-1 
peaks were used to quantify the SERRS and SERS signal responses, respectively. The 
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for antigen quantitation.  
` The SERRS response is markedly different, with only the bands indicative of Cy5 
present, as measured by preparing the capture substrate according to the procedure in 
scheme 3.2. Using the same pretreated 50 ng/mL sample described previously, the 
spectrum closely matches that in figure 3.3. The prominent bands include those indicative 
of the aromatic ring structure at 1598 cm-1, 1355 cm-1, 935 cm-1, 800 cm-1, the polymethine 
bridge stretches at 1405 cm-1 and 560 cm-1, and the gold thiolate stretch at 320 cm-1. The 
peak for the polymethine stretch at 560 cm-1 is used for antigen quantification and, in this 
case, is nearly 80x more intense than the 1336 cm-1 peak from the SERS immunoassay 
analyzed using the same collection parameters (e.g., integration time, number of spectra 
collected, and power density at the sample surface).  
 
3.3.2 Detection of ManLAM in Multiple Sample Matrices 
This set of experiments compared the performance of the SERRS and SERS 
immunoassays when analyzing the same samples. This was accomplished using samples 
composed of ManLAM spiked in an innocuous sample matrix, a solution of 10 mM PBS 
with 150 mM NaCl containing 1% w/v BSA at pH 7.4.44 Figure 3.5 shows the spectra 
collected from the SERRS and SERS assays for ManLAM spiked into PBS (1% v/v BSA) 
at 0.5, 1.0, 5.0, and 10.0 ng/mL, and a blank consisting of only buffer. In both cases, the 
strength of the signal for the RRM increases with ManLAM concentration. However, the 
strengths of the two sets of signal are markedly different, with the SERRS responses 
consistently and significantly higher at a given concentration. From a preliminary analysis 

























Figure 3.5. Spectra for (A) SERRS and (B) SERS immunoassays for ManLAM spiked 
in 10 mM PBS with 1% BSA (pH 7.4). 
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SERS immunoassays, respectively. 
A more in-depth perspective of the differences in the two sets of measurements is 
presented by plotting the intensities of the νs(NO2) at 1336 cm-1 and ν(C-C-C) at 560 cm-1 
as a function of the analytical concentration of ManLAM in the sample for the SERS- and 
SERRS-style immunoassays, respectively. Figure 3.6 presents the dose-response plots 
based on the data in figure 3.5. The signal intensity increases linearly from the blank (0 
ng/mL ManLAM) to the 10 ng/mL ManLAM sample. Interestingly the LOD for the 
SERRS immunoassay (0.8 ng/mL) is ~5x lower than the SERS assay (4.9 ng/mL). A 
comparison of the slopes of the two linear fits, however, shows that there is a larger 
difference between the SERRS [2395 (cts s-1)/(ng/mL)] and SERS [16 (cts s-1)/(ng/mL)] 
assays in analytical sensitivity. This difference represents an increase in the resolving 
power of the SERRS assay (i.e., the ability to resolve differences in ManLAM 
concentrations) by a factor of ~150x. It is important to note that, at the lower 
concentrations, the associated error bars are smaller than the data points, as shown in figure 
3.6. The next set of experiments contrasted the two types of immunoassays using human 
serum as a much more complex sample matrix.44-45, 61-63 
Samples prepared by spiking ManLAM into human serum were used to determine 
the performance of the SERRS immunoassay in a complex sample matrix. Previous work 
in our laboratory has described the initial development of a PCA sample treatment 
procedure to liberate ManLAM so it can be detected effectively in such matrices.44-45 Like 
the experiments summarized in figures 3.5 and 3.6, these samples were examined by 
SERRS and SERS. Figure 3.7 shows the spectra collected from the SERRS and SERS 






Figure 3.6. Dose-response plots for ManLAM spiked into clean sample matrix, 10 mM 
phosphate-buffered saline with 150 mM NaCl at a pH of 7.4, analyzed using both SERS 
(DSNB-modified particles) and SERRS (Cy5-modified substrate). SERRS represents an 
improvement in sensitivity (ratio of the fit lines) of 150x. The determined limits of 
detection are 0.8 ng/mL and 4.9 ng/mL for SERRS and SERS immunoassays, 
respectively. The average and standard deviation arise from 3 replicate samples each. At 
low concentrations, the error bars are smaller than the data points. 
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Figure 3.7. Spectra for (A) SERRS and (B) SERS immunoassays for ManLAM spiked 




with the concentration of ManLAM in the sample, but not nearly at the levels for the buffer 
matrix (figure 3.5). This is attributed to the labile nature of the arabinan sidechains with 
respect to acid hydrolysis and the potential for incomplete protein decomplexation, as 
examined in depth in Chapter 2.31, 36, 44-45, 64 A preliminary analysis of the data suggests the 
LOD for the SERRS assay is unchanged (1 ng/mL), but the LOD for the SERS has 
deteriorated significantly to as high as 50 ng/mL 
For an-indepth analysis, figure 3.8 shows dose-response plots for pretreated 
ManLAM samples analyzed using both assay formats. Using linear best fits to these data, 
the estimated LOD for the SERRS assay (1.1 ng/mL) is on par with the same assay 
performed in a buffer (0.8 ng/mL). The SERS assay functions more poorly with an LOD 
of 10 ng/mL. The average LOD improvement for SERRS from replicate assays is 9.3±0.1. 
It can also be seen that the SERRS assay retains a much higher level of concentration 
resolving power, 38x greater with SERRS, compared to the SERS assay. To gain insight 
into the origin of the improved performance with SERRS, experiments were carried out to 
determine the signal per ERL (described below) for the two assays. 
 
3.3.3 Origin of Observed Increase in Assay Performance 
In looking more deeply into the differences in the strength of the signals in the 
SERRS and SERS assays, the two sets of responses were examined on a per particle level 
by measuring the surface concentration of ERLS at each ManLAM concentration by 
examining SEM images, as shown in figure 3.9. Each image reveals the presence of 
nanometrically sized objects that have a size and shape consistent with the footprints of the 






Figure 3.8. Dose-response plots for ManLAM spiked in a complex sample matrix, pooled 
AB human male serum, followed by a pretreatment method, and analyzed using both SERS 
(DSNB-modified particles) and SERRS (Cy5-modified substrate). SERRS represents an 
improvement in sensitivity (ratio of the fit line) of ~39x. The limits of detection are ~1.08 
ng/mL for the SERRS and ~10.0 ng/mL for the SERS assays. In this regard, the SERRS 
assay is ~10x more sensitive than the SERS assay. The average and standard deviation are 
calculated from 3 replicate samples each. 
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Figure 3.9. Representative scanning electron micrographs of the completed assay surfaces 
for samples containing 50, 10, 5.0, 1.0, and 0.0 ng/mL ManLAM in serum followed by acid 
treatment, by SERRS (A-E) and SERS (F-J). The increase in the size of the image for (J) 




concentration. There are also a larger number of bound particles for the SERRS assays 
relative to the SERS assays. As expected, the particle surface concentrations, obtained 
using Image J software increase with ManLAM concentration, as listed in table 3.3. The 
number of particles on the SERRS substrates are consistently higher than the number found 
on the SERS substrate at each concentration analyzed. Assuming that the particle densities 
determined from the blank samples can be attributed to the nonspecific adsorption of ERLs 
in both the SERRS and SERS assays, the particle densities of the blank samples can be 
subtracted from the particle densities determined at the higher concentrations of ManLAM 
(i.e., 1.0 to 50 ng/mL). This analysis indicates that there is an average increase in particle 
density of 2.02±0.76 ERLs/µm2 for the SERRS immunoassay substrates. While this begins 
to explain the observed increase in analytical sensitivity for the SERRS immunoassay, the 
higher particle density (~2x) alone is insufficient to account for the observed increase in 
analytical sensitivity (~39x).  
To determine the other contributions to the increased analytical sensitivity, these 
results were then combined with the Raman responses from each measurement and the area 
irradiated by the focused laser light in order to calculate the signal per ERL. Using the 
measured area of the focused laser light on the sample surface (69 um2), the signal strengths 
in figure 3.7, and the data in table 3.3, it is possible to calculate the signal per ERL.65-66 
Figure 3.10 shows a dose-response plot of the ERLS on the surface at each ManLAM 
concentration for the SERRS and SERS assay. Even though there are large differences in 
Raman signal, when analyzing the number of ERLS on the surface, the assays have the 
same analytical sensitivity within a 95% confidence interval.67 From an analysis of the data 
using the samples in which the resulting Raman signal is significantly higher than the  
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Table 3.3. Measured ERL surface density as a function of the ManLAM concentration in 
the sample. The average and standard deviation arise from an SEM analysis of 3 replicate 





Measured Particle Density (ERL/µm2) 
 SERS SERRS 
50 2.38±0.24 4.39±0.77 
10 0.73±0.12 1.18±0.36 
5 0.36±0.06 0.74±0.05 
1 0.09±0.01 0.38±0.02 







Figure 3.10. Dose-response plots for ManLAM spiked into human serum, followed by PCA 
treatment, presented as the average number of ERLs interrogated by the laser, for both 
SERS (DSNB-modified particles) and SERRS (Cy5-modified substrate) assays. SERRS 
represents an improvement in sensitivity (ratio of the fit line) of 1.4x. The average and 
standard deviation arise from a combined Raman and SEM analysis of 3 replicate samples 
at each concentration. 
ManLAM (ng/mL)































instrument noise, the average signal per binding event is 21±6 and 1.0±0.1 for the SERRS 
and SERS assays, respectively. This corresponds to a ~21x increase in signal for the 
SERRS assay relative to the SERS assay format. Taking into account the ~2x increase in 
particle density for the SERRS assay and the increase in signal per binding event, the 
calculated improvement in sensitivity for the SERRS immunoassay is 42x greater than that 
for the SERS immunoassay, which agrees well with the observed improvement in 
analytical sensitivity (39x) for the SERRS assay. 
Furthermore, these data suggest that when working with an instrument capable of 
sufficiently sampling a larger part of the substrate, the use of this novel SERRS substrate 
will provide an increase in sensitivity of at least 21x compared to SERS when both assays 
are performing under ideal conditions. Discrepancies are likely due to the assumption that 
the particles are homogeneously and randomly distributed on the assay surface and the 
potential bias induced by undersampling the surface due to the small laser spot size used 
in the Raman analysis.68 Experiments to ascertain the dispersity of ERLs across the 
immunoassay substrates, as well as an investigation into the impact of improved sampling 
methods, are currently underway. However, the experiments described herein have 
demonstrated the improved sensitivities in the detection of a biomarker indicative of TB  
infection, summarized in table 3.4, with the introduction of a novel chemically derived 
SERRS substrate, and additionally, have addressed the potential extensibility of this 




Table 3.4. Determined limit of detection (LOD), analytical sensitivity, slope of dose-
response plot, and signal-to-blank ratio (SBR), calculated at 10 ng/mL for the assay in 
buffer and 50 ng/mL for the assay in human serum. 
 










SERS 4.83 15.9 9.87 10.0 3.43 6.85 





We have described the development of a novel chemically fabricated SERRS 
substrate for the detection of disease biomarkers. We detailed a series of measurements 
and experiments that: (1) characterized thiolated-Cy5 modified immunoassay substrates as 
a component in a novel highly sensitive SERS-enhancing substrate; (2) assessed the 
performance of this new SERRS immunoassay compared to a traditional SERS assay with 
respect to the detection of ManLAM, a biomarker indicative of active TB infections; and 
(3) determined the improvement in analytical sensitivity derived directly from the 
increased particle density on the SERRS substrates and the intrinsic signal amplification 
per binding event of this new SERRS immunoassay relative to the traditional SERS 
immunoassay. This work suggests that the advancement of this novel SERRS 
immunoassay may provide a relatively simple method to detect biomarkers of interest at 
extremely low levels. These new capabilities of this detection strategy may improve disease 
diagnostics and thus help to improve positive patient outcomes. To further understand the 
underpinnings of this new detection strategy, future work will focus on the detailed analysis 
of the dispersion of nanoparticle labels on the immunoassay surface and the further 
implication of under sampling during surface-based measurements. This ongoing work will 
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HANDHELD RAMAN INSTRUMENTATION FOR QUANTITATIVE 
TUBERCULOSIS BIOMARKER DETECTION: FEASIBILITY  
AND IMPLICATIONS FOR POINT-OF-NEED  
INFECTIOUS DISEASE DIAGNOSTICS  
 
4.1 Introduction 
The development of point-of-need (PON) diagnostic tests for the detection of 
disease biomarkers, chemical and biowarfare agents, and environmental contaminants has 
emerged as a global research effort.1-5 The goal is to translate the diagnostic strength of 
today’s advanced in vitro diagnostic tests (e.g., the enzyme-linked immunosorbent 
immunoassay (ELISA) and the nucleic acid amplification test (NAAT)) to modalities that 
can be used beyond the confines of the formal laboratory or clinical setting.1 Many of the 
existing diagnostic tests require secure sample transportation systems, a modern laboratory 
infrastructure, and highly trained personnel, limiting their PON applicability.1, 6-8 In order 
to reduce the burden of infectious disease, particularly in resource-limited regions of the 
world, the development of PON testing methodologies that can overcome the limitations 
of conventional testing is a key first step in the fight against infectious disease.1, 7, 9-10  
The so called “dip stick” tests, like those for human immunodeficiency virus (HIV) 
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detection, are among the most recognized PON diagnostic platforms.11 These tests are 
typically designed for qualitative purposes (i.e., yes/no visual readout), which limits their 
overall utility, particularly with respect to disease staging and monitoring response to 
treatment.11-12 To overcome this limitation, a new generation of quantitative and 
increasingly sensitive PON testing architectures are being developed featuring small 
electronic readers.1, 13 This Chapter examines the utility of a handheld Raman spectrometer 
as a means to assess the potential of, and identify the design needs for, moving 
immunoassays based on surface-enhanced Raman scattering (SERS) readout to PON use. 
In response to the growing importance of PON tests, the World Health Organization 
(WHO) has put forward criteria by which nascent PON diagnostic methods can be 
qualified. The ASSURED criteria was first developed to frame the characteristics of an ideal 
PON test for sexually transmitted infections, but has since been applied to include tests for  
a number of diseases.14-15 ASSURED stands for affordable, sensitive, specific, user-
friendly, rapid, equipment free, and deliverable to those in need. While the equipment-free 
metric originally focused on assays that relied on visual readout, this element of the 
ASSURED criteria has been revised to include backpack portable instrumentation to take 
advantage of more quantitative spectrophotometric, electrochemical, and magnetoresistive 
detection modalities.1, 7, 16-20 Nonetheless, approaches that use an electronic reader must 
still meet all of the other elements of the criteria. This Chapter expands on our work aimed 
at applying SERS detection to tuberculosis (TB) diagnostics to determine how this 
methodology begins to meet the ASSURED metrics and identify the next step necessary to 
move forward.21 
TB is but one of many examples where today’s diagnostic test capabilities fail to 
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meet the ASSURED criteria with respect to deployment in resource-limited regions of the 
world.7, 9, 22 According to the Global Tuberculosis Report 2015 published by the WHO, TB 
now ranks as the world’s deadliest infectious disease.9 It is estimated that 9.6 million 
people developed active TB infections in 2015. Of those, approximately 1 in 7 cases proved 
to be fatal. More so, the report projects that 1 in every 3 individuals who develop TB 
remains undiagnosed/unreported due to limitations in existing testing methodologies, 
access to effective healthcare, economic barriers, and social stigma.1, 9 Bacterial culture 
using patient sputum is the TB diagnostics gold standard.9, 23 However, this test takes 
several weeks to complete and requires a well-developed laboratory infrastructure with 
highly skilled clinicians.1, 9, 22, 24 Tests based on sputum are also ineffective in diagnosing 
extrapulmonary TB infections, which account for ~10% of the TB cases worldwide.9 
 These shortcomings have triggered a refocusing of TB diagnostics to include the 
use of primary antigenic biomarkers indicative of infection. As part of our interest in this 
area, we recently detailed the development of an immunoassay based on SERS for the 
detection of mannose-capped LAM (ManLAM), a major component of the bacterial cell 
wall of M. tuberculosis.21, 25 LAM, a 17.3±5 kDa lipoglycan, consists of a mannosyl 
phosphatidylinositol anchor, an arabinomannan backbone, and a mannose-capping motif. 
5, 22-25 The broad range observed in molecular weight for LAM is indicative of the 
variability in the branching of the side chains, capping, and branching of the backbone.26 
Importantly, the composition of the capping motif differs across mycobacteria. Phospho-
myo-inositol-capped LAM (PILAM) is from M. smegmatis, an often-used nonpathogenic 
simulant for M. tuberculosis.5, 27-39 PILAM is commonly applied as a simulant for 
ManLAM in the development of TB assays because: (1) the two bacteria have very similar 
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genotypes, giving rise to similar cell walls resulting in the shared core structure of PILAM 
and ManLAM; (2) M. smegmatis is a relatively fast growing bacteria and can be readily 
prepared in copious amounts; and (3) M. smegmatis is nonpathogenic and can be handled 
without the biosafety facilities required for M. tuberculosis.30-39 Herein, PILAM (see figure 
4.1 for a generalized structure) will be used as a simulant for ManLAM in an assessment 
of a TB diagnostic test analyzed using a handheld Raman spectrometer. 
 Two of our recent reports have examined the development and preliminary clinical 
accuracy of a sandwich immunoassay for PILAM and ManLAM using SERS detection.21, 
25 This chapter delineates the potential utility of this immunoassay platform (scheme 4.1) 
within the framework of a PON diagnostic test. Our earlier work also showed that this 
platform requires less sample and smaller amounts of reagents when compared to 
immunoassays like ELISA.21, 25, 40-41 Moreover, the large signal enhancement factor for 
SERS (Scheme 4.1), which derives in part from the plasmonic coupling between the gold 
nanoparticle-based labels and underlying gold capture surface, enables the measurement 
of PILAM and ManLAM at low limits of detection (LOD).16, 21, 25, 42 Several other 
characteristics point to the potential value of SERS with respect to field deployability. First, 
the use of long wavelength excitation sources (e.g., 633 nm) minimizes background 
fluorescence from other constituents in the sample matrix.41 Second, Raman scattering is 
relatively insensitive to environmental factors like temperature and humidity and to the 
impact of oxygen and other fluorescence quenchers.43-44 These insensitivities also facilitate 
archiving the completed assays for further analysis and record keeping purposes.  
However, assay development is only the first step in moving this platform towards 





Figure 4.1. The general structure of phosphoinositol-capped lipoarabinomannan 
including the: (1) phosphatidylinositol mannoside (PIM2) anchor, (2) mannan core, (3) 







Scheme 4.1. Outline of the processes and procedures used in the surface-enhanced 
Raman scattering (SERS)-based immunoassay. Both the extrinsic Raman labels (ERL), 
which have a 60 nm gold nanoparticle (AuNP) core, and gold capture substrate are 
prepared prior to running the assay.  
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time, particularly in a forward operating setting (e.g., at remote worksites or mobile 
clinics). To this end, handheld Raman spectrometers have been employed for quality 
control in the pork industry, and to screen for threats from explosives.46-48 However, the 
handheld Raman instrumentation used in these settings is typically limited to determining 
the presence of given compound by comparison to a preloaded spectral library. There are 
few reports beyond that by Zheng et al., which used a handheld Raman spectrometer for 
the semiquantitative detection.13, 49-50 In this case, the detection of a fungicide by labeling 
samples in four groups: no risk, low risk, risk, and high risk, used this type of portable 
reader beyond a qualitative capacity.13, 49-50  
This Chapter expands on the current state of PON diagnostics with SERS by 
investigating the feasibility of applying a handheld Raman spectrometer as an electronic 
optical reader for the immunoassay shown in scheme 4.1 to quantitatively detect PILAM.13, 
21, 25, 51 It describes the testing of a SERS immunoassay designed to detect PILAM spiked 
into human serum with a handheld Raman spectrometer, followed by a series of 
comparative experiments on the analytical figures of merit (i.e., analytical sensitivity and 
LODs) for benchtop and handheld Raman spectrometers. It concludes with a brief 
discussion of the challenges associated with moving this approach forward as a potential 




 Phosphate-buffered saline (PBS) packs (pH 7.4 with 10 mM PBS and 150 mM 
NaCl), borate buffer (BB) packs (pH 8.5 with 50 mM BB), and dithiobis (succinimidyl 
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propionate) (DSP) were purchased from Thermo Scientific. All buffers were prepared with 
18.2 MΩ H2O supplied by a Barnstead ultrapure water system. Tween 20 (T20), 
StartingBlock™, perchloric acid (70%), potassium carbonate, glass microscope slides, and 
sodium chloride were obtained from Fisher Scientific. Bovine serum albumin (BSA) and 
acetonitrile were acquired from Sigma Aldrich. Octadecanethiol (ODT) was obtained from 
Fluka. Polystyrene 24-well microplates and a two-component polydimethylsiloxane 
(PDMS) kit were purchased from Dow Corning. Solid PDMS transfer templates were made 
following the package insert instructions. A UV-curable optical adhesive (#61) was 
obtained from Norland. Colloidal gold (60 nm diameter) at a stock concentration of 2 x1010 
particles/mL was acquired from NanoPartz. Ethanol (200 proof) was purchased from 
Deacon Labs. Pooled AB human male serum was obtained from Innovative Research, Inc. 
Test-grade silicon wafers <1,1,1> were acquired from University Wafer. Gold shot 
(99.995% pure) was purchased from Alfa Aesar. The Raman reporter molecule (RRM) 
5,5’-dithiobis (succinimidyl-2-nitrobenzoate) (DSNB) was synthesized in house per 
procedures detailed elsewhere.42 PILAM and its associated monoclonal capture and tracer 
antibody (CS906.7) were provided by Dr. Delphi Chatterjee and associates at Colorado 
State University.52 
 
4.2.2 Preparation of Extrinsic Raman labels (ERLs) 
 The following sections elaborate more fully on the processes shown in scheme 4.1. 
The fabrication and surface functionalization of ERLs have been detailed elsewhere.40, 42 
In brief, a suspension of 60 nm gold colloids was incubated in a 10 μM solution of DSNB 
and 2 mM BB. This suspension was subsequently agitated by inversion mixing for 30 s 
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and stored at 2-8˚C for 90 min. This step forms a DSNB-derived thiolate monolayer on the 
gold nanoparticles that acts as an RRM and as a coating for the adsorption of monoclonal 
anti-PILAM tracer antibodies. 
The next step imparted immunospecificity to the ERLs by the addition of 
monoclonal anti-PILAM antibodies solubilized in PBS and 0.1% T20 (v/v) (PBST) to the 
colloidal suspension at a final concentration of 1.0 μg/mL. This suspension was also briefly 
mixed by inversion and stored at 2-8˚C for 60 min. The particles were then blocked by the 
addition of a 10% (w/v) BSA solution (2 mM BB) to reach a final BSA concentration of 
1% (w/v). The suspension is again agitated by inversion mixing for 30 s and stored at 2-
8˚C for 60 min. This step coated the particles with BSA, which acts to combat the 
nonspecific adsorption of the ERLs in the antigen labeling step.  
To remove excess reagents, the particles were centrifuged 3x for 10 min at ~2000 
g to precipitate the ERLs, and the colorless supernatant is carefully removed. Between the 
first and second centrifugation steps, the ERLs were resuspended in 1 mL of 1% BSA (w/v) 
(2 mM BB); the final cleanup step concentrated the ERLs in 0.25 mL of 2% BSA (w/v) (2 
mM BB). Finally, a 1.71 M aqueous solution of NaCl was used to adjust the final NaCl 
concentration in the suspension to 150 mM. 
 
4.2.3 Substrate Fabrication and General Immunoassay Procedure  
 The procedures for fabrication of the assay and for performing the immunoassay 
have been described in detail elsewhere.25, 53 In brief, template-stripped gold (TSG) served 
as the solid support for the immunoassay. To fabricate TSG, a clean silicon wafer (100 mm 
diameter) was coated with a thin (180-200 nm) gold film via resistive evaporation at a rate 
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≤ 1 Å/s. After cooling to room temperature, the wafers were removed from the evaporator 
and clean 1x1 cm glass squares cut from microscope slides were affixed across the surface 
using an optical adhesive. The adhesive was cured under UV light for 3 h. When needed, 
the TSG substrates were carefully detached from the Si wafer, exposing the smooth gold 
film on the bottom side of the glass squares.  
Next, the freshly exposed gold surfaces were functionalized with a hydrophobic 
ODT monolayer by contact printing with a PDMS stamp with a 2 mm diameter hole 
centered in the stamp. These stamps were immersed in an ethanolic solution of 1.0 mM 
ODT for ~45 s, and then removed and dried with a gentle stream of high purity nitrogen. 
The dried stamp was gently pressed into conformal contact with the gold surface, creating 
a 2-mm diameter address of unmodified gold surrounded by an ODT hydrophobic barrier 
that confined aqueous solutions within its boundaries in all subsequent assay procedures. 
After removing the stamp, the substrate was rinsed with EtOH and immersed in a 0.1 mM 
ethanolic solution of DSP for 16 h. Finally, the samples were removed from the DSP 
solution, rinsed with EtOH, and dried with a stream of high purity nitrogen. 
The next step arranged the modified TSG substrates in the bottom of a 24-well 
microplate, which was then loaded into a humidity chamber. The substrates were 
functionalized by means of a 20 µL droplet of 2.5 µg/mL (10 mM PBST) monoclonal anti-
PILAM antibody at the center of each address. The humidity chamber was then sealed for 
60 min.54 The substrates were subsequently rinsed with 10 mM PBST, blocked with a 20 
µL droplet of StartingBlock™, and incubated for 60 min in the humidity chamber. The 
substrates were again rinsed with 10 mM PBST and exposed to the antigen-containing 
solutions [i.e., 20 µL droplets of PILAM-spiked human serum which underwent the PCA 
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treatment procedure (section 4.2.4)] for 120 min. The next rinse step used 2 mM BB with 
0.1% T20 (BBT) with 150 mM NaCl, after which captured antigens were labeled for 16 h 
with a 20 µL droplet of the ERL suspension. Finally, unbound ERLs were rinsed off the 
surface with 2 mM BBT with 10 mM NaCl. The completed assay substrates were dried 
under ambient laboratory conditions and analyzed. 
 
4.2.4 Sample Treatment  
 The complexation of PILAM with other human serum constituents requires sample 
pretreatment to release PILAM for low level detection.21, 25 Procedurally, these samples 
were acidified to pH ~1 by the addition of a small amount of 70% perchloric acid. 
Acidification liberates PILAM from complexation by protein denaturation and causes most 
of the serum proteins to precipitate via noncovalent aggregation.55-57 The acidified sample 
was then vortexed for 10 s and centrifuged at ~12,000 g for 5 min to form a pellet of 
denatured proteins and other poorly soluble materials. After centrifugation, a known 
volume of the clear PILAM-containing supernatant was transferred to a new 
microcentrifuge tube and neutralized to pH ~7.5 by the addition of a small volume of 2.0 
M K2CO3. The samples were sequentially stored at 2-8 º C for 60 min to precipitate KClO4, 
after which the PILAM containing supernatant was transferred to another new 







4.2.5 Raman Analysis  
 The completed assay substrates were analyzed using two different benchtop Raman 
and one handheld Raman spectrometers to evaluate the utility of a handheld Raman 
spectrometer for PON diagnostics. A summary of the analysis parameters for the three 
instruments is shown in table 4.1. The substrates were first analyzed using a modified 
NanoRaman instrument (Concurrent Analytical). With this instrument, the output from a 
HeNe (633 nm) laser is fiber optically coupled to a spectrograph consisting of an f/2.0 
Czerny Turner imaging spectrometer (6-8 cm-1 nm resolution) and a thermoelectrically 
cooled (0°C) Kodak™ charged coupled device (CCD). The laser is focused through an 
objective lens (numerical aperture of 0.68) onto the sample surface. The diameter of the 
laser spot on the sample surface is ~30 µm and the measured power at the sample surface 
is 3.02±0.05 mW (i.e., the power density of 4.27±0.07 x10-3 mW/µm2).  
The SERS spectra were collected using 1.0 s integration times at 10 different 
locations about the center of the address with ~150 µm offset between each location. After 
baseline correction, the intensity of the symmetric nitro stretch, νs(NO2), at 1336 cm-1 of 
the RRM on the ERLs was used for analyte quantification. These same substrates were 
analyzed using a handheld Raman spectrometer (Tactic ID, B&W TEK™). This easy-to-
use handheld instrument has a 785 nm excitation source (diode laser) and a linear CCD 
array detector. The spectral resolution is ~7 cm-1. As shown in figure 4.2, this instrument 
has a point-and-shoot configuration and uses a firmly mounted sample holder to place a 
planar sample at a set focal distance for excitation and scattered light collection. Double-
sided tape was used to affix the substrates to the sample holder so that the approximate 
center of the sample could be interrogated. Due to the large spot size (~100 µm) and to
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Table 4.1. Comparison of the collection parameters and assay results for multiple 
instruments used to analyze samples. 
 
Instrument NanoRaman Tactic ID DXR 
Excitation Wavelength 
(nm) 633 785 633 780 
DSNB Scattering 
Wavelength for νs(NO2) of 
RRM (nm) 
691 877 691 871 
Measured Focal Area 
(µm2) α 707 7854
α 69.2 (ellipsoid) 
25.1 
(ellipsoid) 
Power Density (mW/µm2) β 4.27 x10-3 2.41 x10-2 0.101 0.106 
Spectral Resolution (cm-1)α 6-8 9-10 5.2-8.8 4.7-8.7 
Data Spacing (cm-1 per 
point)γ 1.6-2.3
* 4 ~1 ~1 
LOD (pg/mL) 32 179 609** 2958** 
Slope of Dose Response 
Plot 
(cts)/(ng/mL) 
3473±146 646±39 ~556 ~45 
Signal-to-blank Ratio at 1 
ng/mL 68±35 15±12 – – 
αmanufacturer specification. 
βmeasured at sample surface. 
γmanufacturer-specified wavenumber (cm-1) per data point. 
*Interpolated to 1 cm-1. 







Figure 4.2. Digital images of: (A) the handheld Raman instrument and components 
needed for sample measurement, and (B) the sample mounted to the adapter with the 
sample address centered in the adapter. 
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mirror the desired simple “point-and-shoot” application for PON testing, only one location 
on each sample was analyzed using a collection time of 65 s. The laser power measured at 
the sample was 189±1 mW, which translates to a power density of 2.41±0.01 x10-2 
mW/µm2. 
In completing the hardware assessment, a subset of these samples was analyzed 
using a Thermo Scientific DXR Raman microscope in order to directly compare how 
differences in excitation wavelength effect the spectral response and, therefore, assay 
performance. This instrument has interchangeable 633 and 780 nm laser sources. The 
microscope was configured such that the measured power density at the sample surface at 
both excitation wavelengths was nearly identical, ~0.101 and ~0.106 mW/um2 for the 633 
and 780 nm sources, respectively. Spectra were collected from each sample following a 
11x11 grid pattern with 50 µm spacing (121 equally spaced locations), using three 1.0 s 
exposures per location. 
 
4.2.6 External Reflectance UV-Vis Spectroscopy 
The localized surface plasmon resonance (SPR) associated with the ERLs upon 
completion of the assay was measured by external reflection UV-Vis spectroscopy using 
the method described by Driskell et al.58 In brief, spectra were obtained using a Perkin 
Elmer Lambda 650 UV-Vis spectrometer equipped with a Universal Reflectance 
Accessory. The spectra for each sample were collected using p-polarized light at an angle 
of incidence of 58°. The spectra were collected at a resolution of 2 nm and an integration 







where R is the reflectance of the sample and R0 is the reflectance of a bare TSG sample.  
 
4.2.7 Analytical Figures of Merit 
For comparative purposes, two key metrics, LOD and analytical sensitivity, were 
used to define the performance of the three instruments. The LOD is the lowest 
concentration of PILAM that produces a signal statistically distinguishable from 
instrument noise or from the signal from a blank serum sample, a sample that contains no 
PILAM. The LOD concentration is calculated from the average signal of the blank plus 
three times its standard deviation.42 Analytical sensitivity describes how well differences 
in the concentration of PILAM can be resolved. That is, an increase in analytical sensitivity 
corresponds to an increase in the difference in signal from different PILAM concentrations. 
Herein, the analytical sensitivity is described in two ways: (1) the signal-to-blank ratio 
(SBR) for a given PILAM concentration, and (2) the slope of the linear fit line from a dose-
response plot. 
 
4.3 Results and Discussion 
 This section presents the results from experiments designed to evaluate the 
performance of a first generation handheld Raman spectrometer as applied to disease 
diagnostics. It describes: (1) measurements of completed PILAM immunoassays using a 
benchtop Raman spectrometer to serve as a point of reference for assessment of the 
performance of the handheld unit; (2) the effectiveness of handheld Raman instrumentation 
for the detection of PILAM; (3) a brief discussion of the challenges faced in implementing 
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handheld Raman instrumentation for disease detection; and (4) the potential for its 
application in future disease diagnostic measurements. 
 
4.3.1 SERS Measurements 
To establish a comparative set of figures of merit, a benchtop Raman instrument, 
NanoRaman, designed specifically for highly sensitive Raman analysis, was used. Figure 
4.3 shows SERS responses from this instrument after acid treatment of PILAM-spiked 
serum samples prepared at 0.025, 0.05, 0.1, 0.5, 1.0 and 5.0 ng/mL of PILAM. The 
spectrum for an acid-treated serum blank is also included. The spectra have the bands 
indicative of the DSNB coating of the ERLS: ν(C=C) at 1559 cm-1, νs(NO2) at 1336 cm-1, 
ν(C-O), at 1153 cm-1, and ν(N-C-O) at 1079 cm-1.42, 59-60 All of these band intensities 
increase with PILAM concentration.42, 59-60 A cursory examination of the spectra in the 
inset points to an LOD for PILAM of approximately 25 pg/mL.  
The performance of the assay is more fully analyzed through the dose-response plot 
shown in figure 4.4, which was generated by graphing the average intensity for three 
replicate assays of the νs(NO2) at 1336 cm-1 as a function of the spike-in concentration (0-
5 ng/mL) of PILAM. The calculated LOD for PILAM in pretreated serum is 32 pg/mL (1.8 
pM). The SBR at 1 ng/mL of PILAM is 68 and the slope of the linear fit line is 3740 
(cts)/(ng/mL).  
Spectra collected for the same sample spike-in concentrations analyzed using the 
handheld spectrometer (figure 4.2) are presented in figure 4.5. As evident, the strength of 
the signal for these measurements is about 20% those in figure 4.3, and indicates an LOD 





Figure 4.3. Representative SERS spectra collected using a benchtop Raman instrument, 
NanoRaman, for PILAM-spiked human serum samples after PCA treatment. The spectra 
















Figure 4.4. Dose-response plot for PILAM-spiked human serum that underwent PCA 
treatment to remove interferents. The samples were analyzed using a benchtop Raman 
instrument with a 633 nm source and a handheld unit with a 785 nm source. The 
calculated limit of detections (LOD) is 32 pg/mL (~1.8 pM) and 180 pg/mL (~10 pM), 
respectively. The average and standard deviation for the plot are based on 3 separate 
assays. The error bars are smaller than the data points at lower concentration. 
PILAM (ng/mL)
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Figure 4.5. Representative SERS spectra for PILAM-spiked human serum samples after 











generated from three replicate assays is shown in figure 4.4. In this case, the LOD for 
PILAM was 180 pg/mL (10 pM), only ~20% of that for the benchtop instrument. 
Moreover, the SBR at 1.0 ng/mL is 15, which is ~4.5 times less than that for the benchtop 
instrument. And, the slope of the linear fit line, 676 (cts)/(ng/mL), is 5.6 times lower than 
the slope obtained with the benchtop instrument. All three analytical figures of merit for 
the handheld unit are only a factor of ~5 off those for the benchtop system.  
The potential utility of the handheld unit can be framed based on our earlier work 
on the detection of PILAM and ManLAM.21, 25 That work used the same procedures, 
materials and benchtop Raman spectrometer employed to collect the data in figure 4.3, and 
showed that (1) the LOD for ManLAM (~2 ng/mL) is 200x greater than that for PILAM 
(~10 pg/L), and (2) the detectable levels of ManLAM in 21 of the 24 TB-positive (culture 
confirmed) patient samples was ≥10 ng/mL (see table 1 in reference 25).25 If we assume 
the 200x difference in detectability between ManLAM and PILAM found with the 
benchtop Raman spectrometer can be applied to the handheld Raman spectrometer, an 
LOD for ManLAM of ~36 ng/mL can be projected using this portable unit. While only a 
qualitative assessment, and one that remains to be tested experimentally, it appears that the 
handheld Raman spectrometer would have the same clinical specificity as the benchtop 
instrument and only a 30 % drop in clinical sensitivity.25, 61 
There is one additional metric to mention: measurement reproducibility. The 
reproducibility for replicate measurements made with the handheld instrument is greater 
than that of the benchtop instrument, particularly for higher concentration samples. Typical 
values for the coefficient of variance (CV) of 10% can be readily achieved with the 
handheld instrument. The CV when analyzing samples with the benchtop instrument 
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ranges from 5-40%. Laboratory-based instruments typically have high numerical aperture 
objectives to focus the excitation source down to a very small spot (≤30 µm) on the sample 
surface. This is done both to create a higher power density on the sample surface and to 
achieve a higher collection efficiency of the scattered signal, in order to maximize the 
signal from a given sample. Our laboratory recently showed that while high signals at low 
particle coverages can be obtained in this type of immunoassay, using a very small 
measurement area defines the CV, the sampling error, of the measurement of randomly 
disperse ERLs on surface.62 Moreover, this type of sampling error becomes more 
problematic at low surface concentrations, and degrades the LOD.45, 62 
As part of the approach to realize portability, handheld instrumentation often 
forgoes bulky high numerical aperture objectives and simply utilizes a high power output 
diode laser source in order to maintain a high power density at the sample surface of a 
much larger focal area (e.g., ~100-120 µm in diameter). The larger measurement area 
inherently lowers the sampling error, which improves the uncertainty in the measurement 
and, as a consequence, may ultimately lead to improved LODs.62 
 
4.3.2. Moving Toward PON Detection 
Among the chief concerns when using a handheld Raman system is power 
consumption. To be effective for field deployment, the battery must provide power for a 
display/interface system, laser, spectrometer, onboard computer, and other components in 
an easily transportable form factor. This imposes a few key limitations that affect the 
performance of the instrument. First, the more sensitive, thermoelectrically cooled 
detectors require too much power to operate using a battery for long periods. Additionally, 
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several types of laser sources (e.g., HeNe laser at 633 nm), apart from being rather bulky, 
can also draw relatively high power. Handheld spectrometer designers and manufacturers 
therefore favor the use of more energy efficient diode lasers that emit at longer wavelengths 
(e.g., 780 and 785 nm).  
A number of reports have examined the impact of excitation wavelength on the 
achievable enhancement factor (EF) in SERS measurement and, therefore, the overall 
sensitivity of the measurement.58, 63 More to the point, we have shown EF is also dependent 
on the extent of the plasmonic coupling between the ERL and planar gold capture surface 
and how the SPR of the system changes the optimal wavelength for making the 
immunoassay measurements.58, 63 That work demonstrated that the EF is highest when the 
maximum SPR falls midway between the excitation wavelength (λex) and the wavelength 
of the scattered radiation (λsc).58  
Figure 4.6 presents the extinction spectrum measured by the reflectance of a 
completed PILAM assay sample. The extinction maximum is at 618 nm, which represents 
a shift of nearly 80 nm from that of 60 nm gold nanoparticles suspended in 2 mM borate 
buffer (extinction maximum of 540 nm).58, 63 The relevant λex and λsc values associated with 
both the bench top instrument and handheld unit are marked as vertical solid and dashed 
lines, respectively. The extinction maximum for the reflectance measurement is shifted 
from the optimal wavelength (i.e., the midpoint between λex and λsc) by 44 nm and 213 nm 
for the benchtop and handheld spectrometers, respectively. Previous work has shown that 
shifts of 50 nm can decrease the EF by 10-130x.58 By measuring the extinction maximum 
by reflectance UV-Vis for assay samples performed using multiple particle sizes (30-80 










































Figure 4.6. Extinction spectrum measured by reflectance UV-Vis for a 50 ng/mL of 
PILAM sample from a completed immunoassay. The solid vertical lines represent the 
excitation wavelengths (λex), 633 nm (black) and 785 nm (red). The other set of dashed 
vertical lines are for the scattering (λsc) wavelengths for the νs(NO2) band at 1336 cm-1 
of the DSNB-based RRM on the ERLS for the two different excitation sources. The 




size to maximize the EF for the two Raman systems (figure 4.7). To optimize the assay for 
this handheld system would require the use of  ~190 nm gold particles, which is above the 
usable particle sizes typically associated with SERS immunoassays, due to a level of 
sedimentation and the resulting increase in nonspecific particle adsorption.45 
This situation is further compounded by the underlying wavelength dependence of 
Raman scattering in which the scattering intensity (I) is inversely proportional to the 
excitation source wavelength (λex) to the fourth power, equation 4.2, separate from the 
plasmonics of the system.64-66 
 
𝐼𝐼 ∝  1
λ𝑒𝑒𝑒𝑒
4 (4.2) 
Thus, samples analyzed with the handheld using 785 nm excitation should experience a 
signal drop of nearly 60% compared to excitation at 633 nm due solely to the longer 
excitation wavelength. However, this holds true only if all other measurement parameters 
(e.g., power density, collection efficiency, and integration time) for the two instruments are 
matched. 
 To more fully examine the impact of analyzing samples using the handheld 
instrument, it is necessary to measure the samples when using the two different excitation 
wavelengths under an equivalent set of instrumental conditions. For this, we used a Raman 
microscope that has interchangeable 633 and 780 nm excitation sources. The following 
comparative experiments were run setting all of the instrument parameters as closely 
matched as possible (e.g., collection time, number of integrations, and measured power 
density of 0.101 and 0.106 mW/cm2 for the 633 and 780 nm sources, respectively). The 





Figure 4.7. Plot of the measured reflectance extinction maxima as a function of the as-
received gold nanoparticle diameters used in the fabrication of the ERLs. 
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for both excitation wavelengths are shown in figure 4.8. The two expected features, 
indicative of the D and G bands at ~1330 cm-1 and ~1600 cm-1, respectively, of a glassy 
carbon surface, are evident.67-70 The lower signal strengths with longer wavelength 
excitation are consistent with expectations. The theoretical decrease of the D band should 
be 58%, based on the difference in excitation wavelength; however, the measured drop is 
~80%, 235±7 to 47±3 cts for the 633 and 780 nm sources, respectively. This is attributed 
to a difference in throughput of the instrument and the efficiency of the detector at the two 
wavelengths. Taking the intensity ratio of the D and G bands collected using the two 
excitation sources gives an increase in signal of 4.96±0.05x using the 633 nm source 
relative to the 780 nm source. This increase in signal will be used as a wavelength 
correction factor in dissecting the data in the next experiment. 
Figure 4.9 shows representative spectra for completed PILAM assay samples 
analyzed under closely matched collection parameters with both the 633 and 780 nm 
excitation sources. As expected, the signal indicative of the νs(NO2) at 1336 cm-1 increases 
as a function of initial PILAM, concentration and those collected at 780 nm are 
significantly less than those 633 nm. The νs(NO2) intensity at the different PILAM 
concentrations are summarized in figure 4.10. The signal with 633 nm excitation, the more 
optimal plasmonic enhancement condition, is nearly 10 times stronger than that at 780 nm. 
However, after accounting for the difference in excitation wavelength per figure 4.9, the 
improvement in signal with the 633 nm source is ~5x, due to the more favorable 
plasmonics. If we project this improvement in the comparative measurement using the two 
different excitation sources with the Raman microscope, the LOD for PILAM improves to 





Figure 4.8. Raman spectra for a glassy carbon GC sample analyzed using a Raman 
microscope under closely matched conditions using 633 and 780 nm excitation sources. 
The spectra show the expected D and G bands at ~1330 cm-1 and ~1600 cm-1 
characteristic of an amorphous carbon surface. The signal strength for the D band with 










Figure 4.9. Spectra for the same PILAM assay samples analyzed with a Raman 
microscope under matched conditions using excitation source wavelengths 633 nm and 
780 nm. The signal strength of the νs(NO2) obtained with the 633 nm source is 9.5 ± 2.3 














Figure 4.10. Plot of signal intensity of νs(NO2) relative to PILAM concentration for the 
same samples analyzed with a Raman microscope under closely matched conditions 
using excitation source wavelengths of 633 nm and 780 nm. The signal obtained with 






















previously, when using the handheld unit the LOD for ManLAM becomes ~7.4 ng/mL, 
which would give it the same diagnostic accuracy as the benchtop instrument in our 
previous work.25 These results begin to demonstrate the potential utility of handheld Raman 
spectrometers for effectively diagnosing infectious diseases like TB. It is also important to 
recognize that there are other factors that should be considered for more comprehensive 
studies, including data acquisition time and the laser output stability. 
 
4.4 Conclusions 
This Chapter described a series of comparative experiments to gauge the potential 
utility of a handheld Raman spectrometer as a component in moving a SERS immunoassay 
toward PON applications. While focused on the detection of PILAM, a simulant for a 
biomarker for active TB infection, the combined weight of the data indicates that 
realization of this capability with ManLAM is possible in the not-too-distant future, 
especially when designing a portable instrument and support software for the explicit 
purpose of optimizing the plasmonics central to the assay reviewed in scheme 4.1. This 
work begins to establish the ground rules for such an effort. 
There are a number of other challenges to overcome before this transition can 
become reality. These include further studies to validate the clinical utility of the assay 
through extensive tests on several types of TB-positive specimens, including those from 
patients who are both TB-positive and HIV-positive and those with extrapulmonary TB. 
Other factors include the marked reduction in the time required at present to complete the 
assay and the design of reagent packaging, in terms of stability and cost. Importantly, this 
work sets the stage to begin to more fully exploit the extensibility and multiplexing 
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potential of this platform for biomarkers of other diseases, biowarfare agents, and 
environmental pathogens.6, 16, 25, 40, 48, 71-73 Studies along these lines are underway in our 
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5.1 Conclusion and Future Perspectives 
The effective diagnosis of infectious diseases continues to challenge the scientific 
and medical community. Despite the reemergence of some infectious diseases (e.g., 
Tuberculosis (TB), Zika, and Ebola viruses) beyond their endemic regions, people in 
upper-income economies are typically less impacted by their effects due to the availability 
of testing redundancies and access to high quality medical care.1-6 However, the impact of 
infectious diseases in lower-income economies, particularly in areas that overlap with 
endemic regions, is devastating. TB is now the deadliest infectious disease on the planet, 
accounting for 1.37 million deaths in 2015 alone.6 While effective treatment regimens (i.e., 
antibiotics) are in hand, the inadequacies of existing detection technologies (e.g., sputum 
smear microscopy and bacterial culture) result in nearly one-third of all infected people 
remaining undiagnosed.6-10 Efforts to ease the burden of disease associated with TB have 
resulted in a refocusing on the research and development of new and highly sensitive 
detection strategies. While continuing to push the boundaries of knowledge, these 
technological advancements are of little use if, in the end, they are inaccessible to those at 
the point of need (PON). For example, the past decade has seen the development of 
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incredibly sensitive nucleic acid amplification tests for TB, but these tests are often costly, 
time consuming, and require a sophisticated laboratory infrastructure and skilled technical 
staff.6, 8, 11-13 In addition, limited accessibility by the patient population and differing 
attitudes towards healthcare only add to the problem.6, 13-14  
To clearly frame the challenges in meeting this shortfall in effective PON 
diagnostic tests, the World Health Organization has formulated the ASSURED (affordable, 
sensitive, specific, user-friendly, rapid, equipment-free, and delivered to those in need) 
guidelines to direct the development and implementation of PON methodologies.15-16 
Using TB diagnostics and the detection of phospho-myo-inositol-capped LAM (PILAM), 
and mannose-capped LAM (ManLAM) as a model system, this Dissertation has focused 
on approaches towards meeting the challenges faced in modern infectious disease 
diagnostics, while also attempting to drive the eventual transition of laboratory-based 
detection methods toward PON applications within the ASSURED framework. 
Chapter 2 built on previous studies in our laboratory investigating the 
underpinnings of effective sample treatment methods to improve the detection of 
ManLAM.17-18 In this work, two separate sample treatment methods, perchloric acid (PCA) 
and proteinase K (PK), were used to investigate the recovery of the TB antigenic marker, 
ManLAM, from human serum. We showed that while the PCA treatment is ideal from the 
perspective of speed and cost, recovery of ManLAM was hindered through a combination 
of the acid-induced degradation of the arabinan side chains of ManLAM and the partial 
decomplexation of ManLAM from interferents in whole serum. Treatment of serum 
samples with PK, a serine protease, proved more, but not fully, effective. Nevertheless, the 
increase in ManLAM recovery had a significant positive impact on the clinical accuracy 
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of an enzyme-linked immunosorbent assay (ELISA) for the diagnosis of TB-positive and 
TB-negative patient samples.  
The continued optimization of these sample treatment methods is an ongoing 
investigation in our laboratory, along with determining how the extent of ManLAM 
degradation plays a role in its subsequent detection. We believe that these results document 
the unrecognized importance of sample treatment and shed light on the design rules for the 
development of a more effective test for TB and a number of other important infectious 
disease markers.  
Having advanced methods by which PILAM and ManLAM can be rendered 
detectable, the subsequent chapters of this Dissertation assessed the utility of new detection 
strategies for ManLAM and the potential of handheld instrumentation for transitioning 
these and other diagnostic tests beyond the confines of the clinical laboratory. Chapter 3 
described the development, characterization, and validation of a novel surface-enhanced 
resonance Raman scattering (SERRS) detection strategy for improved ManLAM detection. 
This approach utilized infrared external reflection spectroscopy and Raman spectroscopy 
to characterize the chemically modified substrates and to assess surface heterogeneity. This 
work also demonstrated an improved limit of detection (LOD) and analytical sensitivity of 
a SERRS immunoassay for ManLAM over that of our more traditional surface-enhanced 
Raman scattering (SERS) methodology. Finally, this study used scanning electron 
microscopy to begin to identify the origins of the improvement in detection. 
While this study demonstrated an increased ManLAM detectability, measurement 
reproducibility and nonspecific adsorption hindered the ability to fully realize the expected 
level of improvement. We are currently working to more fully characterize the chemically 
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modified substrates with an aim at developing methods to improve the reproducibility and 
to establish approaches to reduce nonspecific adsorption. Nonetheless, this methodology 
shows real promise for realizing ultrasensitive analyte detection with relative ease. 
Moreover, preliminary data suggest that, in some cases, the use of alternate Raman reporter 
molecules (RRMs) on the gold nanoparticle surface used in typical SERS assays has a 
deleterious effect on colloidal stability, thereby reducing assay performance. Because the 
RRM modification is made to the underlying surface in the SERRS assay, as opposed to 
the nanoparticle label, this assay format may be less affected by the issues of particle 
aggregation and colloidal stability observed previously. Furthermore, because of the high 
signals per labeling event, this assay format may further enable the development of 
sensitive SERRS detection with small portable Raman spectrometers.  
Finally, Chapter 4 described the validation of a handheld Raman spectrometer for 
the detection of PILAM spiked into human serum to begin the transition of SERS 
immunoassays towards PON applications. This work validated the instrument performance 
for PILAM spiked into buffer and human serum, demonstrating the ability to achieve low 
LODs for PILAM spiked into serum when detected using a handheld Raman spectrometer. 
This effort also studied the impact of excitation wavelength and the plasmonic interactions 
occurring between the extrinsic Raman labels (ERLs) and underlying planar gold substrate 
as a basis for improving diagnostic assays by choice in excitation wavelength or by 
adjusting, when tractable, the size of the gold nanoparticle used in the ERL fabrication. 
Having demonstrated the potential utility of handheld Raman instrumentation to 
realize the sensitive detection of a TB marker simulant, much of the future work for this 
project revolves around improving performance for ManLAM detection and redesigning 
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the immunoassay into a more amenable PON platform. To improve the sensitivity of the 
readout, we are investigating the impact of particle size on detection. We have also begun 
to build on our past work in solid-phase extraction methodologies as a PON procedure for 
performing immunoassays .19-20 
In closing, we believe that the work described in this Dissertation begins to meet 
some of the challenges faced with the current detection strategies for TB; and, from a 
fundamental standpoint, this work begins to demonstrate the potential applicability of 
sensitive SERS- and SERRS-based measurements outside the confines of the research 
laboratory. Advances in disease diagnostics can be a slow process; however, we feel that 
in building on existing work, the work described herein brings us one step closer to 
realizing methods to combat the burden of infectious diseases, like TB, as well as better 
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